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ABSTRACT
Margiotta, Anna. Enzymatic activation of cannabinoid pro-drugs. Unpublished Master of
Science thesis, University of Northern Colorado, 2018.
Cannabinoids have been used throughout history as medical treatments spanning
from menstrual cramps in ancient China to enhancing appetite in patients with AIDS or
cancer in the modern day. Currently there is research indicating that cannabinoids also
have anti-proliferative and pro-apoptotic effects on several strains of cancer cells
(Carchman, Harris, & Munson, 1976; Glodde, Jakobs, Bald, Tüting, & Gaffal, 2015;
McKallip et al., 2002; Preet, Ganju, & Groopman, 2008; Sánchez, Galve-Roperh,
Canova, Brachet, & Guzmán, 1998). The traditional methods for administration of
cannabinoids are inhalation or oral; however, for some cannabinoids these may result in
undesirable psychoactive side effects. Cell-in-a-Box® technology can be used to develop
a new administration process for cannabinoids to avoid these. In theory, it involves
administering a cannabinoid pro-drug, which is then activated at the site of the cancer
cells via Cell-in-a-Box® encapsulated live cells containing specific enzymes. This
administration process is dependent upon the enzymatic activation of the cannabinoid
pro-drug. Thus, this study focused on determining a cell line capable of producing an
enzyme, which can complete this activation. Five assays of Pseudomonas putida were
conducted, each showing that the putida was not able to activate the specific cannabinoid
pro-drug tested. Future research of other cell lines will be needed to complete this novel
anti-cancer drug delivery system. Additionally, in this study, two methods of producing
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crude cannabinoid extracts from Cannabis sativa plant were developed along with two
methods of purifying tetrahydrocannabinolic acid from the crude extracts.
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CHAPTER I
INTRODUCTION
Plants of the Cannabis genus have been used recreationally throughout history for
their euphoric psychoactive effects. The main psychoactive component of Cannabis
sativa was determined to be ∆9-tetrahydrocannabinol (∆9-THC) (Gaoni & Mechoulam,
1964). Studies investigating the anticancer/antitumor effects of the various plant
components began in the 1970s, and since then evidence supporting these effects has
been compiling.
This study focused on two major cannabinoid components in plants of the
Cannabis genus, ∆9-THC and ∆9-tetrahydrocannabinolic acid (∆9-THCA). ∆9-THC is
responsible for the euphoric, psychoactive effects sought after for recreational use;
however, there is research indicating that it also has anti-proliferative and pro-apoptotic
effects on several strains of cancer cells (Carchman, Harris & Munson, 1976; Glodde,
Jakobs, Bald, Tüting, & Gaffal, 2015; McKallip et al., 2002; Preet, Ganju, & Groopman,
2008; Sánchez, Galve-Roperh, Canova, Brachet, & Guzmán, 1998). Evidence of
anticancer activity of ∆9-THC will be discussed in detail in the literature review. ∆9THCA does not exhibit the same psychoactive effects as ∆9-THC, and it can be converted
to ∆9-THC through a decarboxylation reaction. Thus, administrating ∆9-THCA to a
patient as a pro-drug and converting it to the active drug at the site of the tumor would
allow the cannabinoid’s anticancer activity to occur while avoiding global activation of
cannabinoid receptors by ∆9-THC. This will avoid ∆9-THC’s undesirable psychoactive

2

side effects. The site-selective activation of ∆9-THCA can occur using Cell-in-a-Box®
technology.
Cell-in-a-Box®
Cell-in-a-Box® is a new method of treatment delivery, which was developed by
Austranova, an Austrian biotechnology company. It involves encapsulating geneticallyengineered human cells in a cellulose-based polymeric sphere 0.7-0.8 mm in diameter
(Fig. 1), which can convert an inactive chemotherapy drug into its active form. The cells
are first genetically engineered to contain the desired enzyme capable of activating a prodrug, and then they are sent to the Cell-in-a-Box® facilities where they are encapsulated
in a cellulose-based sphere through a multi-step process (Fig. 2). This treatment of
encapsulation allows for site-specific delivery via injection of the encapsulated cells up
stream in the blood from the tumor (“Live Cell Encapsulation Technology”, 2017). This
is especially helpful when working with cannabinoids with psychoactive side effects
because this site-specific delivery would prevent global stimulation of cannabinoid
receptors. In addition, target-specific treatment with the cannabinoid would allow for
dosage at a lower concentration, which will further minimize the possibility of
psychoactive effects common to ∆9-THC (“Live Cell Encapsulation Technology”, 2017).
In our application, an engineered human embryonic kidney cell possessing genes for
enzymatic decarboxylation of ∆9-THCA would be encapsulated. Human embryonic
kidney cells were chosen for this because the use of human cells would decrease issues of
compatibility with the patient; additionally, these cells have no set life span and can
divide in the Cell-in-a-Box® capsule. At the delivery site of the encapsulated cells the
pro-drug, ∆9-THCA, would be converted to the active drug, ∆9-THC.
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Figure 1: The view of a single Cell-in-a-Box® capsule (From Live Cell Encapsulation
Technology, 2017).

Figure 2: The process for encapsulating live cells in a cellulose sphere by Cell-in-a-Box®
(From Live Cell Encapsulation Technology, 2017).

A major benefit of using this type of technology is its site-specific nature. Many
anticancer drugs are toxic to human tissues and cause the patients to whom the drug is
administered to suffer very serious side effects. Other studies involving the use of
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anticancer drugs with the Cell-in-a-Box® technology suggest that the site-specific nature
decreases the severity and number of these negative side effects. Dr. Matthias Löhr and
his team at the Karolinska Institute in Stockholm, Sweden, have been using the Cell-in-aBox® technology in administering chemotherapeutic drugs for pancreatic cancer. Dr.
Löhr and his research group used encapsulated human 293 cells which were transfected
with genes capable of producing CYP2B1, a cytochrome P450 enzyme capable of
activating the chemotherapy prodrug ifosfamide to its active anti-cancer form (Löhr et al.,
2001). These encapsulated cells were administered to the patient intravenously; the
prodrug ifosfamide was then administered and the active chemotherapeutic drug formed
at the site of the tumor (Löhr et al., 2001). The median survival time for the patients in
this study was doubled when compared to controls. In addition, the one-year survival rate
was increased by three times in the patients included in the study (Löhr et al., 2001). In
an interview, Dr. Löhr reported that the patients included in the initial trial experienced
no side effects, and that the quality of life of the patients was excellent considering their
diagnosis (PharmaCyte Biotech, 2016). The results from these studies suggest that the
Cell-in-a-Box® technology, when combined with ∆9-THCA, will result in the active
drug, ∆9-THC, staying localized at the target. Mostly likely, this will prevent the euphoric
and altered sensory perception side effects most sought after in recreational use, which
result from global cannabinoid receptor stimulation. This should also make this type of
treatment more favorable in the public eye.
The compound ∆9-THC has demonstrated in various studies to have anticancer
activity (Carchman et al., 1976; Glodde et al., 2015; McKallip et al., 2002; Preet et al.,
2008; Sánchez et al., 1998); however, it also exhibits unfavorable psychotropic effects.
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These effects can be avoided through administration of the non-psychoactive ∆9-THCA
combined with Cell-in-a-Box® delivery of a novel human embryonic kidney cell to the
site of the cancer. The novel kidney cell would contain a gene for an enzyme capable of
converting ∆9-THCA to ∆9-THC. The purpose of this study was to determine a cell line
which contains this enzyme. Once the screening for decarboxylation activity in the cell
lines is complete, the specific gene for the enzyme responsible for the conversion will be
identified. This gene will be used to design a novel human embryonic kidney cell line
which will be encapsulated via the Cell-in-the-Box® technology for use with ∆9-THCA.
The ∆9-THCA used for the cell line assays was isolated from Cannabis plant
material in-house. This was due to the high cost of ∆9-THCA standard solution. This
study included two preparations of a crude extract of cannabinoids, one using a Soxhlet
extractor, and one using sonication and solvent to extract. Additionally, there were two
methods developed for isolating ∆9-THCA from the crude extract: one using preparative
high-performance liquid chromatography (HPLC), and one using a Yamazen Smart
Flash.

CHAPTER II
LITERATURE REVIEW
This literature section will begin with general background about the plant
Cannabis sativa, its composition, and how its components interact with the human body
through the endocannabinoid system and cannabinoid receptors. Several studies about the
effect of ∆9-THC on various cancer cell lines will be discussed along with the
corresponding authors’ hypothesized explanations for the effects observed. Finally, the
decarboxylation reaction of ∆9-THCA itself will be discussed along with several cell lines
with enzymes capable of catalyzing similar decarboxylation reactions.
Components of Cannabis
There are over 421 compounds that can be extracted from the plant Cannabis
sativa; these include several types of phytocannabinoids and terpeno-phenols (Izzo,
Borrelli, Capasso, Di Marzo, & Machoulam, 2009). The most abundant psychotropic
component is ∆9-THC, however there are several non-psychotropic cannabinoids
including cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), ∆9tetrahydrocannabivarin (∆9-THCV), cannabidivarin (CBDV), ∆9-THCA, and
cannabidolic acid (CBDA) (Fig.3). ∆9-THC is a strong agonist for both types of
cannabinoid receptors (to be discussed in a following section). ∆9-THCV is an antagonist
for both receptors at low concentrations and an agonist at high doses (10 mg/kg) in vivo
in mice. CBDV, CBG, CBD, ∆9-THC, and ∆9-THCV can increase the amount of
mesenchymal stem cells in bone marrow, which is needed for bone formation and
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fracture healing (Izzo et al., 2009). CBG is a transient receptor potential cation channel
subfamily M member 8 (TRPM8) receptor antagonist and an agonist for transient
receptor potential cation channel, subfamily A, member 1 (TRPA1) receptors (to be
discussed in a following section). CBC, ∆9-THCA, and CBDA are all TRPA1 agonists,
and ∆9-THCA and CBDA are TRPM8 antagonists (Izzo et al., 2009).
Endocannabinoid System
The endocannabinoid system is comprised of endocannabinoids, cannabinoid
receptors (CB1 and CB2), all the enzymes, and molecules responsible for the synthesis,
hydrolysis, and transport of the endocannabinoids (Massi, Solinas, Cinquina, & Parolaro,
2012). ∆9-THC interacts with the human body through binding to both CB1 and CB2
receptors. Endocannabinoids are generally synthesized near the site of the cannabinoid
receptor and released on demand (Massi et al., 2012). They participate in many processes
including regulation of appetite, motor activity, memory, learning, emesis, and
nociception (Fernández-Ruiz et al., 2007). The most bioactive endocannabinoids that
humans synthesize are anandamide (arachidonoylethanolamide, AEA), palmitoylethanolamide (PEA), and 2-arachidonoylglycerol (2-AG) (Fig. 3). These are agonists for
both types of cannabinoid receptors. Other agonists for these receptors include
phytocannabinoids from Cannabis plants, such as ∆9-THC and CBD, and synthetic
cannabinoids, such as WIN55212-2, HU-210, and JWH-015 (Battista, Di Tommaso, Bari,
& Maccarrone, 2012) (Fig. 3).
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Figure 3: Structures of common cannabinoids.
(Battista et al., 2012; Izzo et al., 2009)
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Current clinical use of cannabinoids include treatment for multiple sclerosis,
nausea in cancer patients, and loss of appetite in AIDS patients (Grotenhermen & MüllerVahl, 2012). However, there is therapeutic potential for many other conditions such as
mood disorders, pain disorders, obesity, stroke, hypertension, osteoporosis, and cancer
(Pacher, Batkai, & Kunos, 2006). Moreover, there are many diseases in which afflicted
patients demonstrate an altered endocannabinoid system, necessitating further research
into the endocannabinoid system and cannabinoids. These diseases include spinal cord
injury, neuropathic pain, atherosclerosis, and myocardial infarction (Massi et al., 2012).
Cannabinoid Receptors
CB1 and CB2 receptors are members of the G-protein-coupled family of receptors
and thus are mediated by Gi/o and Gs proteins (Turu & Hunyady, 2010). There are many
signal transduction pathways that are affected due to cannabinoid receptor binding
including inhibition of adenylate cyclase and in some cases, stimulation of adenylate
cyclase (Fig. 4 & 5A). G-protein-coupled receptors can take several different
conformations resulting in these different effects on cAMP production (Turu & Hunyady,
2010). The different conformations are stabilized by the different agonists and
antagonists for the receptor. In some cases, the location of the receptor in the human body
will influence which conformation the receptor will take and thus which down-stream
effects will occur (Turu & Hunyady, 2010). The stimulation of adenylate cyclase results
in the formation of cAMP, which regulates many processes, one of which is the
activation of protein kinase A (PKA) (Fig. 4).
The CB2 receptors in rat microglial cells, hamster ovary cells, and mouse neural
progenitors have been shown to activate the mitogen-activated protein kinase (MAPK)
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cascade via the extracellular-signal-regulated kinases (ERKs) (Fernández-Ruiz et al.,
2007) (Fig. 4). Physiological responses to the activation of the MAPK cascade include
cell proliferation, differentiation, apoptosis, and cell stress response (Plotnikov, Zehorai,
Procaccia, & Seger, 2011). In addition, in human monocyte and leukemia cells the CB2
receptors have demonstrated the ability to activate the p38 MAPK cascade (FernándezRuiz et al., 2007). The p38 MAPK cascade has physiological responses including
regulation of immunological effects, apoptosis, cellular senescence, and induction of
inflammation (Plotnikov et al., 2011). CB1 receptors can also activate the p38 MAPK
cascade (Fig. 5). Of course, the ability of the endocannabinoid receptor to activate these
MAPK cascades represents a certain control of the cell’s survival. Further study of CB2
receptors in rat oligodendroglial cells, rat mast cells, and mouse neural progenitors have
shown that stimulation of the receptors can result in activation of the phosphatidylinositol
3-kinase and Akt pathways, which are both pro-survival mechanisms (Fernández-Ruiz et
al., 2007) (Fig. 4). Thus, the endocannabinoid system plays a role in controlling the cell’s
survival or apoptosis.
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Figure 4: CB2 receptor signaling pathways
(From Fernández-Ruiz et al., 2007, used with permission).

Stimulation of CB1 receptors in a variety of cell types have been shown to activate
the ERKs (Turu & Hunyady, 2010) (Fig. 5). Downstream physiological effects of the
activation of this cascade include proliferation and differentiation of cells, morphological
determination of cells, cell survival, and in some conditions cell apoptosis (Plotnikov et
al., 2011). Stimulation of CB1 receptors can also activate c-Jun N-terminal kinase (JNK)
(Fig. 5). Stimulation of JNK results in the phosphorylation of many substrates which are
involved in gene transcription. Some of the cellular processes resulting from the
transcription of these genes include apoptosis, neuronal activity, and insulin signaling
(Plotnikov et al., 2011).
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Figure 5: CB1 receptor signaling pathways.

In addition, cannabinoid receptor binding results in modulation of ion channels
(Turu & Hunyady, 2010). In both Xenopus laevis oocytes and rat neuronal cells,
stimulation of CB1 receptors resulted in the activation of G-protein-coupled inwardlyrectifying potassium channels (GIRKs) (Turu & Hunyady, 2010) (Fig. 5). CB1 receptors
also influence calcium channels; however, the specific effect depends on the specific cell
investigated. Stimulation of the CB1 receptor can result in inhibition of calcium channels
in cerebral vessels, retinal bipolar cells, and neonatal rat solitary tract cells; however, it
results in activation of calcium channels in mouse neuroblastoma N18TG2 cells (Turu &
Hunyady, 2010) (Fig. 5). In addition, activation of CB1 receptors inhibit the release of a
variety of neurotransmitters including GABA, histamine, serotonin, glutamate,
acetylcholine, and dopamine (Grotenhermen & Müller-Vahl, 2012). Overall, the
endocannabinoid system has many interactions and physiological effects in the central
and peripheral nervous systems, as well as in various peripheral organs and tissues (Turu
& Hunyady, 2010).
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Transient Receptor Potential Cation Channel Receptors
Some cannabinoids have been observed to interact with TRPM8 receptors and
TRPA1 receptors. These include CBG, ∆9-THCA, and CBDA which are antagonists for
TRPM8 receptors. Additionally, CBG, CBC, ∆9-THCA, and CBDA are agonists for
TRPA1 receptors. Both TRPA1 and TRPM8 are involved in the nociceptive process and
are transductors of thermal, chemical, and mechanical stimuli (Izzo et al., 2009). Thus,
the cannabinoids which interact with these receptors have potential use in analgesia or
pain management (Izzo et al., 2009).
Effects of ∆9-Tetrahydrocannabinol on Various
Cancer Cell Lines
Studies exploring the anticancer activity of cannabinoids have focused mainly on
cannabidiol and other non-psychoactive cannabinoids. This is due to the psychoactive
qualities possessed by some cannabinoids such as ∆9-THC, which are undesirable at the
clinical stage of drug design. However, there is ∆9-THC in all strains of Cannabis plants
and there is evidence that CBD and THC have synergistic qualities with each other
(Russo & Guy, 2005). In addition, the application of Cell-in-a-Box® technology as
suggested in this study negates this issue. The following studies explored the effects of
∆9-THC on various cancer cell lines.
Carchman et al. (1976) explored the in vitro effects of various cannabinoids on
DNA synthesis in L1210 leukemia cells and Lewis lung cancer cells. Treatment of the
Lewis lung cancer cells with either ∆9-THC, ∆8-tetrahydrocannabinol (∆8-THC), or
cannabinol (CBN) resulted in a dose-dependent inhibition of tumor growth due to
inhibition of DNA synthesis in the cell. The inhibition of DNA synthesis was measured
by incubating the cancer cells with either one of the cannabinoids or ara-C, a known
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inhibitor of DNA synthesis, and then measuring the uptake of radiolabeled thymidine by
these cells. Incubating the cells with ara-C resulted in a low uptake of thymidine and an
ED50 of 1.36×10-7 M for Lewis lung cells and 2.53×10-8 M for L1210 cancer cells.
Incubating Lewis lung cells with ∆9-THC, ∆8-THC, ABN ∆8-THC, or CBN resulted in a
low uptake of thymidine, like that of the ara-C, and had ED50 values of 4.18×10-6 M,
2.99×10-6 M, 1.48×10-6 M, and 2.3×10-6 M, respectively. Incubating L1210 with ∆9-THC,
∆8-THC, ABN ∆8-THC, or CBN resulted in a low uptake of thymidine, and had ED50
values of 3.26×10-5 M, 8.70×10-6 M, 5×10-6 M, and 2.2×10-6 M, respectively. In vivo
testing using B6D2F male mice which were inoculated with Lewis lung carcinoma cells
occurred. The mice which were treated with either THC or CBN had significantly smaller
tumors than those which were not treated (Carchman et al., 1976).
The Carchman study also included treatment of bone marrow cells with the
cannabinoids and ara-C to assess their toxicity, and of all the treatments the least toxic
was ∆9-THC. The ∆9-THC ED50 for both types of cancer cells included in this study was
about 100 times higher than the ED50 of ara-C (Carchman et al., 1976). Ara-C has been
shown to cure L1210 in vivo, and this study revealed a similar activity caused by the
cannabinoids. In addition, the cannabinoids had a lower toxicity to bone marrow than the
ara-C.
Preet et al. (2008) investigated the effects of ∆9-THC on A549 and SW-1573 lung
cancer cells both in vitro and in vivo. They reported that ∆9-THC inhibited the epidermal
growth factor (EGF) receptor, which inhibited migration of the cancer cells in vivo that is
normally triggered through EGF pathways. Specifically, this was caused through ∆9-THC
inhibition of AKT and MAP kinases which are both important for cancer cell migration.
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∆9-THC reduced tumor growth and metastasis in vivo in the severe combined
immunodeficient (SCID) mice tested. In addition, they reported that, after 72 hours of
treatment with ∆9-THC in vitro, apoptosis resulted in both A549 and SW-1573 lung
cancer cells. They also observed that in vitro ∆9-THC induced EGF-controlled
morphological changes which reduced motility of both cell lines.
Glodde et al. (2015) investigated the role of CB1/CB2 receptors in the
pathogenesis of HCmel12 melanoma cells, as well as the effect of ∆9-THC on these cells
in vitro and in vivo. They determined endocannabinoids do not have a role in the
pathogenesis of melanoma using chemically-inducing tumors on wild-type mice and
CB1/CB2 receptor knock-out mice and monitoring the growth of their tumors. Treatment
of melanoma cells with ∆9-THC during culturing had no effect on their proliferation.
However, in vivo treatment of HCmel12 cells with ∆9-THC in mice resulted in a
significant decrease in the size of their tumors. They hypothesized that since the ∆9-THC
did not affect the cells in vitro their antitumor activity in vivo must be due to the ∆9-THC
interaction with the immune system or the angiogenesis of the cancer cells. Cannabinoids
as a class have a well-established effect on the immune system, and one characteristic of
HCmel12 melanoma cells is an increase of myeloid immune cells in their specific
environment. In another related study, the authors displayed ∆9-THC’s ability to both
diminish allergic swelling and limit the influx of immune cells to the allergen’s contact
site (Gaffal, Cron, Glodde, & Tüting, 2013). This combined information supports the
hypothesis that ∆9-THC diminishes tumor cell growth via preventing pro-tumorigenic
myeloid immune cells from entering the melanoma cell environment (Glodde et al.,
2015).
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McKallip et al. (2002) exposed two murine lymphomas (EL-4 and LSA), and a
murine mastocytoma (P815) cancer cell line to ∆9-THC to observe its effect. In vitro ∆9THC concentrations of at least 10 μM resulted in reduction of the number of cancer cells
and an increase in apoptosis for El-4, LSA, and P815 cell lines. The occurrence of
apoptosis was confirmed through dying the cells with annexin and propidium iodide (PI).
Cells that dye positive with annexin are in early apoptosis, cells that dye with both are in
late apoptosis, and cells that dye positive for just PI alone are necrotic. Most of the cells
treated with THC tested to be in late apoptosis. In vivo testing of ∆9-THC on the EL-4
cell line in C57BL/6 mice resulted in a reduction of tumor size in most samples (77.3%)
and 25% of the mice were cured of their tumors all together (McKallip et al., 2002).
Sánchez et al. (1998) explored the effects of ∆9-THC on C6.9 glioma cells. Due to
the variability and heterogenous nature of C6 glioma cells, a previously characterized sub
clone of these cells, C6.9 cells, were used for characterization of apoptosis for this study.
In vitro administration of ∆9-THC to these cells in concentrations as low as 0.75 μM
resulted in a significant decrease in their optical density assessed via a MTT assay. This
is indicative of a significant decrease in metabolic oxidation in the cells. There was
eventual cell death. This effect was also shown to be dose-dependent. A fluorescent
annexin V binding assay was also performed which showed a loss of plasma membrane
asymmetry in cells treated with the ∆9-THC. DNA fragmentation was seen in the cells
treated with ∆9-THC; both observations are typical results of apoptosis. They
hypothesized that the mechanism of the programmed cell death is linked to
sphingomyelin breakdown. In the same study, the addition of ∆9-THC to the cell medium
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solution resulted in significant breakdown of sphingomyelin, which resulted in a buildup
of ceramide, a widely documented inducer of apoptosis (Sánchez et al., 1998).
Enzymatic Decarboxylation Reaction
∆9-THCA can be decarboxylated to produce in ∆9-THC (Fig. 6). This reaction
most commonly occurs through the burning or heating of Cannabis plant material
containing ∆9-THCA (Wang et al., 2016). However, there are many types of cells that
have enzymes capable of performing decarboxylation reactions. The carboxylic acid
group ortho to a phenolic hydroxyl group theoretically could be enzymatically removed
from the ∆9-THCA to form the ∆9-THC (Fig. 6). Thus, the enzymes that were screened in
the current study to determine decarboxylation activity of the ∆9-THCA were those that
have been shown to have this type of activity with compounds that have an ortho
hydroxyl group to the targeted carboxylic acid.
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Figure 6: Enzymatic decarboxylation of ∆9-THCA to produce ∆9-THC.

6-Methylsalicylic acid decarboxylase is an enzyme coded by the PatG gene, and
its substrate is 6-methylsaliylic acid, which has a hydroxyl group ortho to the carboxylic
acid that the enzyme catalytically removes (Fig. 7). There are many cell lines that code
for this enzymatic activity, including Aspergillus clavatus, Aspergillus giganteus,
Aspergillus longivesica, Byssochlamys nivea, and Penicillium expansum (Snini et al.,
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2013). In Aspergillus clavatus, the PatG gene is responsible for encoding the enzyme
which performs this decarboxylation (Snini et al., 2013).

Figure 7: Enzymatic decarboxylation of 6-methylsalicylic acid to produce m-cresol.

Another enzyme whose substrate has a hydroxyl group ortho to a carboxylic acid
is salicylic acid decarboxylase (Fig. 8). This enzyme is produced by the fungus
Trichosporon moniliiforme, and it decarboxylates salicylic acid as well as with other
carboxylated substrates (Kirimura, Gunji, Wakayama, Hattori, & Ishii, 2010).

Figure 8: Enzymatic decarboxylation of salicylic acid to produce phenol.

2,3-Dihydroxybenzoic acid is a substrate for 2,3-dihydroxybenzoic acid
decarboxylase; it also has a hydroxy group ortho to the carboxylic group to be removed
(Fig. 9). This enzyme is produced by several Aspergillus fungi including Aspergillus
oryzae and Aspergillus niger (Santha, Rao, & Vaidyanathan, 1996).
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Figure 9: Enzymatic decarboxylation of 2,3-dihydroxybenzoic acid to produce 1,2dihydroxybenzene (catechol).

1,2-Dihydro-1,2-dihydroxybenzoic acid (DHB) is an intermediate in the
formation of catechol from benzoic acid. DHB dehydrogenase is involved in the final
step of this reaction, converting the intermediate to catechol (Fig. 10). Like ∆9-THCA this
intermediate has a hydroxyl group ortho to the carbon bearing the carboxylic acid to be
removed. This enzyme is produced in Acinetobacter calcoaceticus, Alcaligenes
eutrophus, Pseudomonas cepacia, and Pseudomonas putida (Reiner, 1971).
O
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Figure 10: Enzymatic decarboxylation of 1,2-dihydro-1,2-dihydroxybenzoic acid to
produce catechol.

Another decarboxylation enzyme synthesized by Pseudomonas putida is
benzoylformate decarboxylase (Iding et al., 2000). This enzyme catalyzes the
decarboxylation of benzoylformate to benzaldehyde (Fig. 11). Like ∆9-THCA this
substrate has an aromatic ring and a carboxylic acid.
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Figure 11: Enzymatic decarboxylation of benzoylformate to produce benzaldehyde.

Pseudomonas putida was used in preliminary studies exploring activation of
cannabinoid-like model compounds and succeeded in decarboxylating the model
compound (Cribbs, 2016). Thus, Pseudomonas putida was used for the microbial cell line
assays in this study.

CHAPTER III
METHODS AND MATERIALS
Reagents and Materials
Cannabidiol (CBD) (item number 90080), cannabidiolic acid (CBDA) (item
number 14028), and a mixture of cannabinoid standards (item number 18791) were
obtained from Cayman Chemical Company. The mixture of cannabinoids contained 100
μg/mL of each of the following: CBDA, cannabigerolic acid (CBGA), cannabigerol
(CBG), CBD, tetrahydrocannabivarin (THCV), cannabinol (CBN), ∆9tetrahydrocannabinolic acid (∆9-THCA), ∆9-tetrahydrocannabinol (∆9-THC), ∆8tetrahydrocannabinol (∆8-THC), and cannabichromene (CBC). Water was purified in
house using a QTUM 000 EX Millipore water purification system to obtain HPLC-grade
water. Tryptic soy broth/agar (item number 470015-844), MRS broth/agar (item number
89405-526), and brain heart infusion broth/agar (item number 90000-062) for cell media
were purchased from VWR International. ∆9-THC (item number T2386), HPLC-grade
methanol (item number 34860-4L-R), ammonium formate (item number 540-69-2), and
HPLC-grade hexane (item number 293253-4L) were purchased from Sigma-Aldrich.
HPLC-grade acetonitrile (item number A998-4), HPLC-grade pentane (item number
P399-4), absolute ethanol (item number BP2818-4), activated charcoal (item number
C170-500), and potassium hydroxide (item number M-10489) were purchased from
Fischer Scientific. Formic acid (item number UN1779) and chloroform-d (item number
865-49-6) were purchased from ACROS Organics. Silica gel 60 RP-18F TLC plates with
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fluorescent indicator (item number 115685) from Merck were used when producing the
Yamazen method. Cell lines containing decarboxylation enzymes were obtained from
VWR International. Marijuana plant material (RTI log number 13494-22, reference
number SAF 027355, 13.5% ∆9-THCA) was obtained from the National Institute on Drug
Abuse.
Instrumentation
Analytical High-Performance
Liquid Chromatography
Method
HPLC analysis was used to determine the presence and relative ratios of ∆9-THC
and ∆9-THCA in samples. The HPLC used was a Shimadzu (Tokyo, Japan) VP equipped
with an analytical Luna Omega 5 μm Polar C18 100 LC column 150×4.6 mm with a
4.0×3.0 mm guard column. The HPLC was equipped with a DGU-14A degasser, one LC10AT pump, and a Rheodyne injector with a 10 μL injection loop. It also had a Shimadzu
SCL-10A system controller and a SPD-M10A diode array detector. All solvents were
filtered (0.22 μm filter) before being run through the HPLC; all aqueous solvents and
methanol were filtered through a nylon filter and all other organic solvents were filtered
through a Teflon filter. Solvent A was 20 mM ammonium formate, pH 3.20, and solvent
B was HPLC-grade acetonitrile. A twenty-minute-long gradient method was used with
the analytical column; this started with 60% B raised to 95% B over nine minutes, held at
95% B for three minutes and then reduced back to 60% B over four minutes and held at
60% until the twenty-minute mark. This was run with a flow rate of 1.2 mL/min. The
HPLC system used the CLASS-VP 7.2.1 SP1 software program to generate all
chromatograms.
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Preparative High-Performance
Liquid Chromatography
Method
A preparative method for purifying ∆9-THCA from a crude cannabinoid extract
used a Shimadzu VP HPLC equipped with a preparative Luna Omega 5 μm Polar C18
100 LC column 150×21.2 mm with a polar C18 SecurityGuard prep cartridge, 15×21.2
mm. The HPLC was equipped with a DGU-14A degasser, two LC-10AT pumps, and a
Rheodyne injector with a 1.0 mL injection loop. The HPLC also had a CBM-10AW
communications bus module and a SPD-10A UV-VIS detector. A Gilson FC-100 Micro
Fractionator was used with the preparative column to collect the compounds separated by
the HPLC. Solvent A was 20 mM ammonium formate, pH 3.20, and solvent B was
HPLC-grade acetonitrile. A 120-minute-long gradient method was used with the
preparative column, starting with 25% B for five minutes then raised to 95% B over 65
minutes; the concentration was held at 95% B for ten minutes before being decrease to
25% B over 30 minutes. The concentration was held at 25% B until the 120-minute mark.
This was run with a flow rate of 5.0 mL/min. The CLASS-VP 7.2.1 SP1 software
program was used to generate all chromatograms.
Yamazen Method
A second method of isolating ∆9-THCA was developed using a Yamazen Smart
Flash EPCLC A1-5808. The Yamazen was equipped with a S W826 silica gel inject
column and a 2L ODS-SM 50 μm 120 Å universal column. The solvent system used with
the Yamazen was 80% acetonitrile, 10% methanol, and 10% 20 mM ammonium formate,
pH 3.20. The chromatographic method was set up using the Yamazen’s automatic system
and a TLC plate which was spotted with crude cannabinoid extract and developed using
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the same solvent system described above. The Rf value for the ∆9-THCA was 0.25 which
was entered in the automatic set-up (Fig. 12). The Yamazen automatic chromatographic
method set-up does not have a setting for only a single line to be used, so both lines A
and B were placed into a container of the aforementioned pre-mixed solvent system, and
the mixing ratio was set to 99:1. Finally, the elution mode was set to isocratic, and the
flow rate automatically set to 20 mL/min. The software displayed the approximate time
that the target will elute and the volume of solvent used at this time (342 mL in this case)
(Fig. 12). Additionally, the UV detector was set at a wavelength of 254 nm.

Figure 12: Automatic chromatographic method set-up of the Yamazen Smart Flash
EPCLC A1-5808.
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Proton and Carbon Nuclear
Magnetic Resonance
Method
Samples from both the Yamazen method and the preparative HPLC method of
purifying crude cannabinoid extract were analyzed via proton NMR. The samples were
dried in a stream of N2 gas, and the residue was dissolved in 600 μL of deuterated
chloroform for the analysis. A Bruker 400 MHz NMR was used, and the TOPSPIN 1.3
software program was used to generate all spectra. To determine the identity of the
cannabinoids, the spectra were compared to standards of the cannabinoids from literature
(Fig. 13). Figure 13 depicts the H-1’’ peaks at approximately 2.78 ppm and 2.94 ppm as
well as the H-1 doublet at approximately 3.23 ppm and was compared directly to the
proton NMR spectrum produced in this study. A study by Hazekamp et al. classify H-5’
and H-2 as identifying peaks of ∆9-THCA, which are located at 6.39 ppm and 6.24 ppm,
respectively. Additionally, a carbon NMR of the extract collected via the preparative
HPLC method was compared to the carbon NMR of a ∆9-THCA standard in the Choi et
al. study (2004).

Figure 13: Proton NMR identifying peaks of ∆9-THCA with numbering of ∆9-THCA and
∆9-THC according to Choi.
(From Choi et al., 2004, used with permission).
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Infrared Spectroscopy Method
The 4 mg/mL ∆9-THCA solution prepared after the isolation of ∆9-THCA via the
preparative HPLC method was analyzed using IR. A Nicolet iS5 equipped with a iD5
ATR accessory using the OMNIC software was used for this analysis. This IR spectrum
was compared to a spectrum of a ∆9-THCA standard in a study completed in 2016 by
Smith, Lewis, and Mendez.
Additional Instrumentation
Mass measurements were made using either an Ohaus® GA200D balance or a
Denver Instrument XE-510 balance. A Cole-Palmer, handheld short/long-wave UV light
was used to visualize the spots on developed TLC plates. The pH measurements of the
ammonium formate solution were made using a Fisher Scientific Accumet® AB150 pH
meter. The pH meter was calibrated using Fisher scientific pH 4.00, pH 7.00 and pH
11.00 buffer solutions. A Büchi Rotavapor® R 110 was used for evaporating solvents.
Rainin Pipetman micro pipettes ranging from 20 μL to 5000 μL were used when making
sample or standard solutions and transferring cell lines during the decarboxylation assay.
During the decarboxylation assay, the cells were incubated with a VWR International
constant temperature shaking water bath incubator. When the cells were extracted with
pentane, the media and solvent were mixed in a capped test tube using a VWR scientific
Bronwill mixer, and then the tubes were centrifuged using an International clinical
centrifuge made by International Equipment Company.
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Procedures
Preparation of Solutions
Ammonium formate (20 mM ) solution was prepared by adding 0.6306 g of
ammonium formate to a 500-mL volumetric flask and diluting with HPLC-grade water.
A 20 mM solution of formic acid was made to adjust the pH of the ammonium formate
solution to a pH of 3.20. The 20 mM formic acid was prepared by adding 0.3835 mL of
96% formic acid to a 500-mL volumetric flask and diluting with HPLC-grade water. The
pH of the ammonium formate solution was monitored with the Fisher Scientific
Accumet® AB150 pH meter while the 20 mM formic acid solution was slowly added
until the solution reached pH 3.20. This ammonium formate buffer solution was used in
the solvent system for the analytical HPLC method, preparative HPLC method, and
Yamazen Smart Flash method.
During cell growth incubation, Pseudomonas putida bacterial cells were treated
with 70 mL of 0.011 M salicylic acid to induce the decarboxylation enzymes. The total
volume of the bacterial cell in media with the salicylic acid was 770 mL, so the overall
concentration of the salicylic acid was approximately 0.0010 M. This salicylic acid
solution was prepared by dissolving 0.3798 g of salicylic acid in 25 mL of ethanol with
0.169 mL of 4 M KOH in a 250-mL volumetric flask, and then diluting to volume with
water.
The ∆9-THC standard from Sigma Aldrich was used to make a 1.2 mg/mL
solution in ethanol, and a 5.0 mg/mL solution in ethanol. The standard from Sigma
Aldrich was a 24 mg/mL solution in ethanol. The 1.2 mg/mL solution was made by
taking 0.050 mL of the stock solution, transferring it to a mini vial, and adding 0.95 mL
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of ethanol. The 5.0 mg/mL solution was made by taking 0.099 mL of the stock solution,
evaporating the ethanol using N2 gas to obtain 2.38 mg of residue, and then dissolving
that in 0.46 mL ethanol.
Crude Extraction of Cannabinoids
from Marijuana Plant Material
Sonification method. Initially, 1.0 g of starting plant material, obtained through
the National Institute on Drug Abuse, was freeze-dried using a Labconco Freezone 4.5
then pulverized with a mortar and pestle. The dry material was extracted in 20 mL
pentane containing 20 μL glacial acetic acid through sonication on ice for two minutes.
The sample was sonicated with a Branson digital sonifier for 15-second-long bursts at a
time at 10% amplitude and allowed to cool on ice for thirty seconds between bursts,
totaling eight bursts. It is possible for the vibration of the sonifier’s tip to heat the
solution which could cause the ∆9-THCA to be converted to ∆9-THC, which is why the
solution was sonicated in bursts and on ice to prevent this (Wang et al., 2016). Following
sonification this solution was stirred at room temperature on a stir plate for an hour. After
one hour, an additional

20 mL of pentane was added, and the solution was stirred for

an additional 45 minutes. The extract was filtered through a Fisher Scientific P5 filter
paper, treated with 0.5 g activated charcoal, and refiltered. The sample was concentrated
using a rotary evaporator at 30 ˚C yielding a brown, viscous residue. This residue was a
crude extract of cannabinoids which was further purified using chromatography.
Soxhlet method. A second method of producing a crude extract of cannabinoids
was developed using a Soxhlet extractor. This consisted of placing 100 mL of pentane in
a 250 mL round-bottom flask and 5.0 g of freeze-dried marijuana plant material in a
thimble filter in the Soxhlet attachment. The round-bottom was attached to the Soxhlet
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and attached on top was a condenser (Fig. 14). The round-bottom was heated to a gentle
boil at 40 ˚C using a variac and a heating mantle. This set up was run for three hours. The
round-bottom was then detached, the pentane evaporated using the rotary evaporator, and
the remaining brown, viscous residue was the crude extract of cannabinoids.

Figure 14: Image of Soxhlet setup.
Isolation of ∆9-Tetrahydrocannabinolic Acid
Yamazen Smart Flash. Exploratory TLC silica gel 60 RP-18F plates with
fluorescent indicator from Merck were developed with either hexane, acetonitrile,
acetone, ethyl acetate, methanol, or dichloromethane using crude cannabinoid extract as
the sample. The purpose of TLC was to explore which solvent systems gave an Rf value
of approximately 0.2 for the sample ∆9-THCA to determine which solvent to use with the
Yamazen Smart Flash EPCLC A1-5808 when purifying the crude extract. The solvent
system determined with the TLC was 80% acetonitrile, 10% methanol, and 10% 20 mM
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ammonium formate, pH 3.20. Before the flash chromatography could begin, the
Yamazen system was first primed by pumping line A for 2 minutes at a flow rate of 10
mL/min, and then line B for two minutes at a flow rate of 10 mL/min. Then the column
was equilibrated by pumping the mobile phase solvent system for ten minutes at a flow
rate of 30 mL/min. After this, the automated chromatographic method began, which was
23 minutes long and used 460 mL of mobile phase total (Fig. 12). The method was used
with a sample of crude extract (1 mL), which was injected into the Yamazen using the S
W826 silica gel inject column onto a 2L reverse phase ODS-SM 50 μm 120Å universal
separation column. After this analysis was complete, HPLC-water was pumped through
line A for two minutes at a flow rate of 20 mL/min, and then HPLC-water was pumped
through line B for two minutes at a flow rate of 20 mL/min. This was done to remove any
lingering ammonium formate from the instrument. In total, this method uses 800 mL of
mobile phase and 80 mL of water each time it is used.
During the automated chromatographic method, the major peaks were collected
from the Smart Flash, and each sample was placed in a 50-mL round-bottom flask and
the organic solvent evaporated using a rotary evaporator, leaving behind the aqueous
layer. Pentane (7.5 mL) was added to the flask and it was vigorously shaken. The pentane
layer was removed with a pasteur pipette, evaporated, and the sample residue resuspended in 0.1 mL absolute ethanol. Each sample was analyzed with the Shimadzu VP
HPLC using the analytical column.
Preparative High-Performance Liquid Chromatography. A second method of
purifying the crude extracts was developed using preparative HPLC. A sample of crude
extract (0.5 mL) was injected into the HPLC equipped with the preparative Luna Omega
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5 μm Polar C18 100 LC column. The peaks were collected using a Gilson FC-100 Micro
Fractionator, which was set to shift to a new collection test tube every three minutes. The
test tubes were numbered in the order in which they were collected, and the peaks were
assigned to which test tube they were in based on their elution time. The major peaks
were collected from the fractionator, and each sample was placed in a 50-mL roundbottom flask and the organic solvent evaporated using a rotary evaporator, leaving behind
the aqueous layer. Pentane (7.5 mL) was added to the flask and it was vigorously shaken.
The pentane layer was removed with a pasteur pipette, evaporated, and the sample
residue re-suspended in 0.1 mL absolute ethanol. Each sample was analyzed with the
Shimadzu VP HPLC using the analytical Luna Omega 5 μm Polar C18 100 LC column
150×4.6 mm.
Prior to the preparative HPLC chromatographic method being used, an isocratic
method of 75 % line A (20 mM ammonium formate, pH 3.20), and 25% line B (HPLCgrade acetonitrile) was run for 20 minutes at a flow rate of 5 mL/min. This was to
completely remove the solution in which the column is stored and to achieve a baseline.
After the preparative HPLC chromatographic method is complete, an isocratic method of
70% line A (HPLC-grade methanol), and 30% line B (HPLC water) was run for 10
minutes at a flow rate of 5 mL/min. This is the solvent system in which the column is
stored. In total, the preparative HPLC chromatographic method uses 750 mL of solvent
each time it is used.
Infrared Spectroscopy Method
A sample of the 4 mg/mL solution of ∆9-THCA obtained via preparative HPLC
(0.25 mL) was transferred to a vial, and the ethanol in which the sample was dissolved
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was evaporated by running N2 gas over it. The remaining residue (1 mg) was dissolved in
a minimal amount of hexane. The hexane solution was dropped onto the crystal of the
iD5 ATR accessory for the Nicolet iS5, and the hexane evaporated. This left behind only
the solid ∆9-THCA residue on the crystal, which was then analyzed.
Cell Growth and Assay
Studies referenced in the literature review section exploring different microbial
species capable of decarboxylating aryl carboxylic acids were used to determine the cell
lines to screen for their ability to decarboxylate ∆9-THCA.
Pseudomonas putida was tested for decarboxylation activity. The Pseudomonas
putida cells were cultured in 500 mL of MRS agar at 37 ˚C. The cells were fed every two
days with 200 mL of fresh media. The Pseudomonas putida cells grew for five days
before being induced with salicylic acid, and then they were incubated for an additional
two days. The cells were centrifuged in 50-mL conical tubes at 4000g for 10 minutes.
The remaining cell pellet was weighed and then resuspended in 25 mL of appropriate
culture medium. Lysed cells were used to alleviate any issues there may have been with
diffusion or transporting the ∆9-THCA across membranes. The cells were lysed through
sonification with a Branson Digital sonifier. The samples were sonicated at a 10%
amplitude for ten seconds, the sonication paused for one second, and then sonicated again
for ten seconds. This method was repeated twice for each cell sample.
To evaluate if the cells chosen will decarboxylate the ∆9-THCA, 16.0 mL of the
cell suspension plus 0.10 mL of ∆9-THCA were incubated and 2.0 mL aliquots of the
media were removed at various times to analyze with the HPLC to determine the
presence of ∆9-THC. The concentration of the ∆9-THCA used is specified in appendices
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D-H. Cells were incubated in a water bath at 37 °C with gentle shaking. The 2-mL
aliquots were taken at 0, 1, 2, 3, 4, 5 and 6 hr. The cannabinoids were extracted from the
2-mL media aliquot using 5.0 mL pentane containing 0.5 mL ethanol. The extract was
evaporated to dryness with N2, and the residue containing cannabinoids was resuspended
in 0.10 mL ethanol and analyzed via HPLC. The second through the fifth assays had an
identical control solution of bacteria and ∆9-THCA which had aliquots taken at the same
time as the experimental solution. The only difference between the control and the
experimental solution was that the control was autoclaved beforehand to inactivate all
enzymatic activity. Thus, if enzymatic decarboxylation activity was observed in the
experimental aliquot samples, this would not be seen in the control aliquot samples. The
first assay conducted did not have a control.
Comparison of ∆9-Tetrahydrocannabinolic Acid Yield Between
Preparative High-Performance Liquid Chromatography
Method and Yamazen
Method
The yield of the two methods of isolating ∆9-THCAwere compared. A Soxhlet
extraction was performed, the mass of the crude extract recorded, and then a solution of
the crude extract was injected in to the preparative HPLC and the Yamazen Smart Flash.
The mass of the residue presumed to contain ∆9-THCA was measured after it was
collected from both the preparative HPLC and the Yamazen Smart Flash. After this each
of the residues presumed to contain ∆9-THCA were dissolved in ethanol to make a
2 mg/mL solution, and then each analyzed via the analytical HPLC method to confirm
they contain ∆9-THCA. The CLASS-VP 7.2.1 SP1 software program was used to
determine the percent area under the curve of the ∆9-THCA peak for the whole
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chromatogram in each sample. This was then used to determine the actual mg of ∆9THCA in each and then the percent ∆9-THCA in the total equivalent mass of marijuana
plant injected. This percentage was then compared to the percentage of ∆9-THCA
reported on the label (13.5%) of the marijuana plant received from the National Institute
on Drug Abuse.
Construction of Calibration Curve
for ∆9-Tetrahydrocannabinolic
Acid
Prior to assessing the ability of a cell line to decarboxylate the ∆9-THCA, a
calibration curve was constructed by graphing different concentration samples of ∆9THCA against the area under the curve of the peak detected for each with the analytical
HPLC. A 4 mg/mL solution of ∆9-THCA in ethanol was prepared from ∆9-THCA
obtained using the preparative HPLC method. Serial dilution of the 4 mg/mL ∆9-THCA
produced a 2, 1, 0.5, and 0.25 mg/mL solutions. This was repeated using three different
starting 4 mg/mL solutions obtained from preparative HPLC runs to make triplicates of
each concentration. Each solution was analyzed via the analytical HPLC method, the area
under the curve of the peak was obtained using the CLASS-VP 7.2.1 SP1 software
program, and the calibration curve constructed by plotting these areas against the
corresponding concentration of the sample. Since triplicates of each concentration were
analyzed, the area under the curve used for the calibration curve were the average of the
triplicates.
Construction of Calibration Curve
for ∆9-Tetrahydrocannabinol
If decarboxylation activity is observed, the concentration of ∆9-THC produced
can be determined through using a calibration curve. The calibration curve was
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constructed by plotting different concentration samples of ∆9-THC against the area under
the curve of the peak detected for each with the analytical HPLC. A 5 mg/mL solution of
∆9-THC in ethanol was obtained by diluting the standard obtained from Sigma-Aldrich.
This was used to make three 4 mg/mL solutions of ∆9-THC. A serial dilution of each of
the 4 mg/mL ∆9-THC solutions was made to produce solutions containing 2 mg/mL, 1
mg/mL, 0.5 mg/mL, and 0.25 mg/mL. Each solution was analyzed via the analytical
HPLC method, the area under the curve of the peak was obtained using the CLASS-VP
7.2.1 SP1 software program, and the calibration curve constructed by plotting these areas
against the concentration of the sample. Since triplicates of each concentration were
analyzed, the area under the curve used for the calibration curve were the average of the
triplicates.

CHAPTER IV
RESULTS AND DISCUSSION
Isolation of ∆9-Tetrahydrocannabinolic Acid
Analytical High-Performance Liquid Chromatography Assessment
of Cannabinoid Standards
Standards of cannabinoids were analyzed via the analytical HPLC method to
determine their elution times. This was done for ∆9-tetrahydrocannabidiol (∆9-THC),
cannabidiol (CBD), cannabidolic acid (CBDA), and a mixture of cannabinoids containing
CBDA, cannabigerolic acid (CBGA), cannabigerol (CBG), CBD, tetrahydrocannabivarin
(THCV), cannabinol (CBN), ∆9-tetrahydrocannabinolic acid (∆9-THCA), ∆9-THC, ∆8tetrahydrocannabidiol (∆8-THC), and cannabichromene (CBC) (Fig. 15 – 18). Some drift
of the standard peaks was observed so many assessments of the standards were
performed. From this it was determined that the elution time for each of the cannabinoids
is dependent on whether they are in a mixture. In addition, the elusion time for a standard
may vary depending on the solvent in which it is dissolved and if the gradient method
does not have enough time to re-equilibrate after each sample analysis.

Figure 15: Analytical HPLC method chromatogram of ∆9-THC standard (1.2 mg/mL in
ethanol).
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Figure 16: Analytical HPLC method chromatogram of cannabinoid mixture standard
containing CBDA, CBGA, CBG, CBD, THCV, CBN, ∆9-THCA, ∆9-THC, ∆8-THC, and
CBC (100 μg/mL each in acetonitrile).

Figure 17: Analytical HPLC method chromatogram of CBD standard (1.2 mg/mL in
ethanol).

Figure 18: Analytical HPLC method chromatogram of CBDA standard (0.1 mg/mL in
ethanol).

38

Phenomenex, the company which made the analytical column used for the
analytical HPLC method, released a chromatogram of a mixture of cannabinoid standards
analyzed using the Luna Omega Polar C18 100x2.1 mm column with a similar 20 mM
pH 3.20 ammonium formate and acetonitrile method as used in this study. Through
comparing their chromatogram (Appendix A) with Figures 16 - 19, the peaks in Figure
16 can be assigned. In Figure 16, the peak at 4.9 minutes is CBDV, the peak at 7.9
minutes is mostly likely both CBD and CBDA, the peak at 8.2 minutes is most likely
both CBGA and CBN, the peak at 9.9 minutes is ∆9-THC, the peak at 10.9 minutes is
CBC, and the peak at 11 minutes is ∆9-THCA (Appendix A; Fig. 15 – 18).
A reverse phase method was used for the analytical HPLC column. Traditionally,
reverse phase methods consist of using a polar mobile phase and a non-polar stationary
phase. ∆9-THCA, since it has an extra carboxylic group would be expected to be more
polar than ∆9-THC, and thus have a shorter elution time. However, there is intramolecular
hydrogen bonding in ∆9-THCA which does not exist in ∆9-THC. This causes ∆9-THC to
behave more polar than ∆9-THCA and thus it had a shorter elution time than ∆9-THCA
using the analytical HPLC method.
In addition, the solvent in which the sample is dissolved when injected into the
analytical HPLC will affect the elution time. This can be seen when comparing the ∆9THC standard chromatogram with the mix of cannabinoids chromatogram. The ∆9-THC
standard is dissolved in ethanol and the ∆9-THC eluted at 10.0 minutes, whereas the
mixture of cannabinoids are dissolved in acetonitrile and the ∆9-THC eluted at 9.9
minutes (Fig. 15 and 16). The CBD standard is dissolved in ethanol and eluted at 8.4
minutes, whereas the CBD in the mixture eluted at 7.9 minutes (Fig. 16 and 17). The
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CBDA standard is dissolved in ethanol and eluted at 7.1 minutes whereas the CBDA in
the mixture eluted at 7.9 minutes (Fig. 16 and 18). The ∆9-THCA in the mixture of
cannabinoids eluted at 11.0 minutes (Fig. 16). The samples from the microbial cell assay
that were injected into the analytical HPLC were dissolved in ethanol, thus the elution
time for the ∆9-THCA in these samples should have a slightly shorter elution time than
the ∆9-THCA in the mixture of cannabinoids.
Crude Extraction of Cannabinoids
From Marijuana Plant Material
Both the sonication and the Soxhlet methods of extracting a crude mix of
cannabinoids from plant material were successful. Samples of the crude extract were
prepared for isolation of ∆9-THCA by placing 1 mL of absolute ethanol into the roundbottom flask in which the extract was collected at the end of both crude extraction
processes and vigorously shaken (see Methods). The 1.0 mL volume of ethanol should be
saturated with cannabinoids and then used for the isolation of ∆9-THCA by injecting into
either the Yamazen or the preparative HPLC. Both methods of obtaining crude extract
provided an adequate mass of ∆9-THCA to be isolated and further using in the cell line
assays. The Soxhlet method allowed for a greater mass of plant material to be extracted
compared to the sonication method; 5.0 g versus 1.0 g, respectively. Further, the Soxhlet
method required no human interaction during the three-hour extraction after the initial
setup, whereas the sonication method required several steps of interaction during its
approximately two-hour long extraction. Thus, comparatively the Soxhlet method was a
more useful method of producing the crude extract since it allowed more time for the
cannabinoids to dissolve into the solvent, and it was very simple in execution.
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Yamazen Chromatography
Chromatograms of the samples of cannabinoids were developed using reversephase TLC plates to determine what solvent system would result in a cannabinoid extract
having an Rf value for THCA of approximately 0.2. This was done because the Yamazen
Smart Flash uses an image of the TLC plate to set up its chromatographic method, and an
Rf value of approximately 0.2 for the compound of interest is recommended for this. The
final solvent system which was used was 80% acetonitrile, 10% methanol, and 10% 20
mM ammonium formate, 3.20 pH. This gave a Rf value of 0.25 (Fig. 19). The spots on
this plate were visualized using an ultraviolet light.
Since there was no available standard of ∆9-THCA to compare the crude extract
via TLC, additional TLC plates were developed which were spotted by a crude
cannabinoid extract made from marijuana plant material of high CBD content and a crude
cannabinoid extract made from marijuana plant material of high ∆9-THCA content (both
of which were made through the Soxhlet extraction method). This was done to determine
where the ∆9-THCA would appear on the TLC plate through comparing these two
extracts. Comparing these, the ∆9-THCA was identified by observing a larger spot in the
cannabinoid extract made from marijuana plant material of high ∆9-THCA when
compared to the cannabinoid extract made from marijuana plant material of high CBDA
(TLC plates not pictured). The ∆9-THCA from this plate was used when developing the
TLC plate which was used for the Yamazen chromatography (the spot on the right in
Figure 19). The spot on the left in Figure 19 is crude cannabinoid extract (made through
the sonication method). In Figure 19 both of these samples have a major spot at an Rf of
0.25, which was presumed to be ∆9-THCA.
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Figure 19: Image of TLC plate used for developing the Yamazen Smart Flash method.
Left lane is crude cannabinoid extract, right lane is ∆9-THCA obtained from an
unpictured TLC plate.

Four peaks were collected from the Yamazen (Fig. 20). The first peak was from
time 0.25 min to 0.67 min, the second peak was from time 2.75 min to 5.17 min, the third
peak was from time 5.17 min to 11.42 min, and the fourth peak was from time 11.42 min
to 19.67 min (Fig. 20). The organic solvent was evaporated from each peak using a
rotary evaporator and the remaining aqueous layer was extracted with 7.5 mL pentane to
collect all cannabinoids. The pentane was evaporated via open-dish evaporation, and the
remaining reside was weighed and dissolved in 0.1 mL absolute ethanol to be analyzed
via analytical HPLC.
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Figure 20: Yamazen chromatogram obtained after injecting 1.0 mL crude cannabinoid
extract solution.

The fraction under each of the Yamazen peaks were individually injected into the
Shimadzu HPLC equipped with the analytical column. The first two Yamazen fractions
(representing peaks 1 and 2) had no significant peaks corresponding to ∆9-THCA when
analyzed with the analytical HPLC method. Fraction 3 had a significant peak at
approximately 12.5 minutes (Fig. 21). Fraction 4 had a significant peak at a slightly later
elution time (13.5 min). This sample was used as the ∆9-THCA in the first three
microbial cell assays. The solvent was evaporated from this sample and the remaining
residue weighed. The residue was dissolved in 5.65 mL of absolute ethanol to produce a
4 mg/mL solution.

Figure 21: Analytical HPLC method chromatogram of fraction 3 (from Figure 20).
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Figure 22: Analytical HPLC method chromatogram of fraction 4 (from Figure 20). The
peak at 13.5 min was presumed to be ∆9-THCA.

In addition to analysis via HPLC, each of the four fractions collected from the
Yamazen were also analyzed via proton NMR (Appendix B). Both fraction 3 and fraction
4 from Figure 20 appear to contain ∆9-THCA when comparing each of their spectra (Fig.
23 & 24, respectively) to the literature ∆9-THCA NMR spectrum (Fig. 13). Additionally,
the NMR spectra (both Figures 24 and 25) have peaks at approximately 6.39 ppm and
6.24 ppm which can be assigned according to Hazekamp et al. as peaks in ∆9-THCA
(2004).
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Figure 23: Proton NMR chromatogram of fraction 3 (from Figure 20).

Figure 24: Proton NMR chromatogram of fraction 4 (from Figure 20).
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Figure 25: Zoom of proton NMR chromatogram of fraction 4 (from Figure 20).

In Figure 24, a carboxylic acid proton is seen at approximately 12.2 ppm. In
addition, when Figure 24 is compared to the literature standard ∆9-THCA spectra
reported by Hazekamp et al. the peaks for H-2 and H-5’ at approximately 6.2 and 6.4
ppm, respectively, are visible (2004). Comparing Figure 25 to the literature standard ∆9THCA spectra (Fig. 13), both the H-1’’ peaks at approximately 2.78 ppm and 2.95 ppm
are visible as well as the H-1 doublet at approximately 3.23 ppm are visible. These
observations indicate that fraction 4 from Figure 20 collected from the Yamazen
chromatography contains ∆9-THCA. All these peaks are also seen in the NMR spectra for
fraction 3 from Figure 20. The major peak at approximately 7.3 ppm is due to a small
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amount of chloroform present in the chloroform-d used as the solvent for the NMR (Fig.
23). Fraction 4 was used for some of the microbial cell assays.
Preparative High-Performance
Liquid Chromatography
Several components were separated using the preparative HPLC and collected
into test tubes using the Gilson FC-100 Micro Fractionator. Figure 26 is the
chromatogram for the preparative separation of 0.5 mL of crude extract produced through
Soxhlet extraction. Due to the fractionator, each peak seen on the chromatogram was
collected in a numbered test tube, which are recorded for the major peaks in Figure 26.

Test tube 25

Test tube 26

Test tube 24
Test tube 23

Test tube 22

Test tube 14

Figure 26: Preparative HPLC chromatogram of 0.5 mL of crude cannabinoid extract.

Each of the major fractions collected from the preparative HPLC method were
analyzed via proton NMR and analytical HPLC (Appendix C). The organic solvent was
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evaporated from each test tube with a rotary evaporator followed by extraction of the
aqueous solvent with pentane, evaporated to dryness, and the mass of the residue was
determined. Fraction 14 was from elution time 38.97 to 41.97 min, fraction 22 from
62.97 to 65.97 min, fraction 23 from 65.97 to 68.97 min, fraction 24 from 68.97 to 71.97
min, fraction 25 from 71.97 to 74.97 min, and fraction 26 from 74.97 to 77.97 minutes
(Fig. 26). Before being analyzed via NMR, each sample was dissolved in 600 μL of
deuterated chloroform. The fraction collected in test tube 26 appeared to contain ∆9THCA through comparison of its NMR spectra (Fig. 27 – 28) with the ∆9-THCA
standard literature spectra (Fig. 13). Additionally, the NMR spectrum (Figure 27) has
peaks at approximately 6.39 ppm and 6.24 ppm which are identified by Hazekamp et al.
as peaks in ∆9-THCA (2004).

Figure 27: Proton NMR spectra of fraction 26 (from Figure 26).
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Figure 28: Integration and chemical shift of proton NMR spectra of fraction 26 (from
Figure 26).
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In Figure 27, a carboxylic acid proton is seen at approximately 12.21 ppm. In
addition, when Figure 27 is compared to the standard ∆9-THCA spectra by Hazekamp et
al. the peaks for H-2 and H-5’ at approximately 6.2 and 6.4 ppm, respectively, are present
(2004). Comparing Figure 28 to the standard ∆9-THCA spectra (Fig. 13), both the H-1’’
peaks at approximately 2.78 and 2.95 as well as the H-1 doublet at approximately 3.25
are present. These observations indicated that this sample contains ∆9-THCA.
Table 1
Comparison of Proton NMR Spectra of Fraction 26 (from Figure 26) with Proton NMR
of ∆9-THCA reported by Choi et al. (2004).
Carbon Position in ∆9-THCA
1
2
3 – Me
4
5
6
8
9
5’
1’’
2’’
3’’
4’’
5’’
COOH

Chemical Shift in Choi
study (2004) (ppm)
3.23
6.39
1.68
2.17
1.92, 1.35
1.67
1.44
1.11
6.26
2.94, 2.78
1.57
1.35
1.35
0.90
12.19

Chemical Shift from
Figure 28
3.23
6.39
1.68
2.18
1.93, 1.25
1.72
1.44
1.11
6.26
2.95, 2.79
1.57
1.35
1.35
0.90
12.18

The proton NMR spectrum (Figure 28) was compared to the proton NMR
spectrum of ∆9-THCA reported by Choi et al. (2004). Each of the observed peaks in both
spectra have similar chemical shifts; the data from Figure 28 and the data presented by
Choi et al. are compared side by side in Table 1. The largest difference between any of
the chemical shifts in Figure 28 and the chemical shifts from the Choi study is 0.10 ppm
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(Table 1). The numbering of the carbons used in Table 1 is the same numbering used in
Figure 13. Fraction 26 from Figure 26 was also analyzed via carbon NMR and the peaks
observed compared to the peaks reported by Choi et al. (2004).

Figure 29: Carbon NMR spectra of fraction 26 (from Figure 26).

The carbon NMR spectrum (Figure 29) was compared to the carbon NMR
spectrum of ∆9-THCA reported by Choi et al. (2004). Each of the observed peaks in both

51

spectra have similar chemical shifts; the data from Figure 29 and the data presented by
Choi et al. are compared side by side in Table 2. The largest difference between any of
the chemical shifts in Figure 29 and the chemical shifts from the Choi study is 0.4812
ppm (Table 2). The numbering of the carbons used in Table 2 is the same numbering
used in Figure 13.
Table 2
Comparison of Carbon NMR Spectra of Fraction 26 (from Figure 26) with Carbon NMR
of ∆9-THCA reported by Choi et al. (2004).
Carbon Position in ∆9-THCA
1
2
3
3 – Me
4
5
6
7
8
9
1’
2’
3’
4’
5’
6’
1’’
2’’
3’’
4’’
5’’
COOH

Chemical Shift in Choi
study (2004) (ppm)
33.5
123.6
133.8
23.3
31.2
25.0
45.6
78.8
27.4
19.6
109.9
164.7
102.3
146.9
112.6
159.8
36.5
31.3
32.0
22.5
14.1
176.2

Chemical Shift from
Figure 29
33.5
123.6
133.9
23.4
31.2
25.0
45.7
78.9
27.4
19.5
109.9
164.7
102.3
147.1
112.7
159.8
36.5
31.3
32.1
22.6
14.1
176.7

After NMR analysis, the deuterated chloroform was evaporated from the sample
collected in fraction 25 (from Figure 26) by running N2 gas over it. A 4.0 mg/mL solution
of the remaining residue was made by adding 1.425 mL of absolute ethanol. A serial
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dilution of this solution was made to construct a calibration curve of the ∆9-THCA
solution using the analytical HPLC method. The 4.0 mg/mL solution from fraction 26
(from Figure 26) was also injected into the analytical HPLC to compare it to analytical
HPLC analysis of the mixture of standard cannabinoids to determine the elution time of
∆9-THCA and its purity.

Figure 30: Analytical HPLC analysis of 4.0 mg/mL solution of fraction 26 (from Figure
26).

The most significant peak in Figure 31 has an elution time of approximately 10.75
minutes. This was the only peak in the solution detected at an intensity above 100 mAu.
Comparing this peak to the mix of standard cannabinoids chromatogram (Fig. 16), along
with examining the proton NMR spectra of this compound, the peak in Figure 31 can be
identified as ∆9-THCA and its elution time is approximately 10.75 minutes. Additionally,
a 1 mg sample of the ∆9-THCA collected from fraction 26 (Fig. 26) was analyzed via IR.
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Figure 31: IR analysis of 4 mg/mL solution of fraction 26 (from Figure 26).

The IR spectrum in Figure 31 has a very broad peak starting at approximately
2400 cm-1 and ending at approximately 3600 cm-1. This type of peak is indicative of a
carboxylic acid. Additionally, there is a sharp peak at 1617.30 cm-1 and a sharp peak at
1257. 32 cm-1. These are indicative of a C=O stretch and a C−O stretch, respectively.
Comparing this spectrum to the IR spectrum by Smith, Lewis, and Mendez (2016), both
have a broad carboxylic acid peak, along with sharp peaks at approximately 1250 cm-1.
Additionally, the C=O stretch peak in the Smith, Lewis, and Mendez paper is as 1614.42
cm-1 which corresponds to the C=O stretch in Figure 31 at 1617.30 cm-1. Further, both
spectra have similar sp3 carbon stretches at approximately 2800 cm-1. This provided
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further confirmation that the contents of fraction 26 collected via preparative HPLC
(Figure 26) contain ∆9-THCA.
Comparison of ∆9-Tetrahydrocannabinolic Acid Yield
Between Preparative High-Performance Liquid
Chromatography Method and Yamazen
Method
A Soxhlet extraction of 5.01 g of 13.5% ∆9-THCA marijuana plant was completed
using 100 mL of pentane. The 250 mL round-bottom flask used for this extraction was
weighed before and after it contained the dried crude cannabinoid extract. The mass of
this extract was 1.0451 g. This residue was dissolved in 6.0 mL of ethanol and transferred
to a test tube. Aliquots of this 0.1741 g/mL crude cannabinoid solution was then injected
into both the preparative HPLC (0.25 mL aliquot) and the Yamazen Smart Flash (0.50
mL aliquot). The data used to determine the percent yield of each method are presented in
Table 3.
These results indicate that the preparative HPLC method was able to isolate
99.3% of the ∆9-THCA in the marijuana plant received by the National Institute on Drug
Abuse, whereas the Yamazen Smart Flash was able to isolate 27.1% of the ∆9-THCA in
the marijuana plant.
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Table 3
Comparison of ∆9-THCA Yield Between Preparative HPLC Method and Yamazen
Method
Fraction

Preparative
HPLC
Volume of crude cannabinoid extract injected (mL)
0.25

Yamazen
Smart Flash
0.50

Equivalent mass of crude cannabinoid extract
injected (mg)

44

87

Equivalent mass of marijuana plant injected (mg)

210

420

Mass of residue presumed to contain ∆9-THCA
collected from instrument (mg)

36

20

77.7

76.7

28

15

% ∆9-THCA collected from original mass of plant
material injected

13.4

3.66

% Yield of ∆9-THCA based on percent ∆9-THCA
in the marijuana plant reported by the National
Institute on Drug Abuse (13.5%)

99.3

27.1

Analytical HPLC percent area under the curve of
∆9-THCA peak
Mass of ∆9-THCA in residue collected from
instrument (mg)

Calibration Curve for ∆9-Tetrahydrocannabinolic Acid
The 4 mg/mL solution of ∆9-THCA which was isolated via preparative HPLC
(Fig. 30) was used to make triplicates of different concentrations of ∆9-THCA to be
analyzed via analytical HPLC. The concentration of the solutions made in triplicate were
4 mg/mL, 2 mg/mL, 1 mg/mL, 0.5 mg/mL, and 0.25 mg/mL. The area under each peak
was determined using the CLASS-VP 7.2.1 SP1 software program. The data are
presented in Table 4.
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Table 4
Calibration Curve Data for ∆9-THCA Using the Analytical HPLC Method
Concentration (mg/mL)

4

2

1

0.5

0.25

0.125

0.0625

Area under the curve for
each triplicate (area units)
51311413
53793629
48684559
31260848
34462434
33824056
24010586
22920013
25278396
15092733
13417926
16755497
6729947
7936614
7648819
2042008
4089147
7108877
4399080
3404844
4439564

Average area under the
curve (area units)
51263200

33182446

24069665

15088719

7438460

4413344

4081163

Each injection resulted in a chromatogram similar to that in Figure 31, that is,
there was only one major peak which eluted at 10.75 minutes. A standard curve was
generated and is presented in Figure 32. When analyzing the samples from the cell line
assays via analytical HPLC, the equation from Figure 32, y = 1E+07x + 6E+06, can be
used to determine the concentration of ∆9-THCA in each sample.
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Average area under the curve (area units ×106)

70
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50
40

y = 1E+07x + 6E+06
R² = 0.9554
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20
10
0
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4.5

Figure 32: Calibration curve for ∆9-THCA using the analytical HPLC method.
(Detector at 254 nm)
Calibration Curve for ∆9-Tetrahydrocannabinol
A 5 mg/mL solution of ∆9-THC in absolute ethanol was made from the ∆9-THC
standard. This was used to make triplicates of different concentrations of ∆9-THC to be
analyzed via analytical HPLC. First, three 4 mg/mL solutions were made by taking
0.16 mL of the 5 mg/mL solution and adding 0.04 mL of absolute ethanol. Then a serial
dilution occurred using each of the 4 mg/mL solutions. The concentration of the
additional solutions made in triplicate were 2 mg/mL, 1 mg/mL, 0.5 mg/mL, and 0.25
mg/mL. Each injection resulted in a chromatogram similar to that in Figure 15, that is,
there was only one major peak which eluted at 10.0 minutes. The area under each peak
was determined using the CLASS-VP 7.2.1 SP1 software program. The data are
presented in Table 5.
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Table 5
Calibration Curve Data for ∆9-THC Using the Analytical HPLC Method
Concentration (mg/mL)

4

2

1

0.5

0.25

Area under the curve for
each triplicate (area units)
26024291
29802271
28361482
21636759
22961743
22175662
18434083
19054194
18254328
16044129
16906442
15362906
15155494
14208841
13314282

Average area under the
curve (area units)
28062681

22258055

18580868

16104492

14226206

A standard curve was generated and presented in Figure 33. When analyzing the
samples from the cell line assays via analytical HPLC, the equation from Figure 33,
y = 4E+06x + 1E+07, can be used to determine the concentration of ∆9-THC in each
sample.
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Average area under the curve
(area units ×106)
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Figure 33: Calibration curve for ∆9-THC using the analytical HPLC method.
(Detector at 254 nm)
Assessment of ∆9-Tetrahydrocannabinolic Acid
Decarboxylation in Different Cell Lines
Five assays of Pseudomonas putida were conducted to determine the ability of the
microbial cells to decarboxylate ∆9-THCA. The data from these assays suggest that
Pseudomonas putida is unable to decarboxylate ∆9-THCA. The chromatogram for each
aliquot taken in each assay, along with the specific volume and concentration of cells
used in each assay, and concentration of ∆9-THCA used are found in Appendices D – H.
First P. putida Assay
All the chromatograms of aliquots taken in this assay are found in Appendix D.
Initially, this assay appears to show some decarboxylation activity since a peak at
approximately 10.7 minutes, which was not present in the time = 0 hr aliquot, appears in
the time = 1 hr, time = 5 hr, and time = 6 hr chromatograms (Fig. D4, D12, & D13). This
peak elutes at approximately the same time as the ∆9-THC standard peak which was
analyzed before the assay aliquots (Fig. D2). However, this peak does not appear in the
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time = 2 hr, time = 3 hr, and time = 4 hr aliquots (Fig. D8, D10, & D11). Additionally,
when some of these aliquot samples were reanalyzed via analytical HPLC, there were
major inconsistences between the peaks seen in samples when comparing the first and
subsequent analyses of the same sample. The time = 1 hr chromatograms (Fig. D4, D5,
D6, & D7) vary significantly, with only the first chromatogram (Fig. D4) displaying
either the ∆9-THC or the ∆9-THCA peaks. The repeats of the time = 2 hr aliquot analyses
(Fig. D8 & D9) also show major inconsistences with only Figure D9 showing a ∆9THCA peak. Finally, since there was no control assay run alongside this one, the peaks
which appear to elute at the same time as ∆9-THC (Fig. D4, D12, & D13) could be from
compounds extracted from the microbial growth media. Thus, all assays after this had
control assays to more easily identify a ∆9-THC peak, if one is present, and allow for the
identification of peaks resulting from the extraction of compounds in the growth media.
Second P. putida Assay
All the chromatograms of aliquots taken in this assay are in Appendix E. The ∆9THC standard was analyzed before the microbial aliquot samples and revealed that the
∆9-THC peak eluted at 11.9 minutes. There was only one major peak for the time = 0 hr
aliquot and the time = 0 hr control aliquot, which was at time 12.7 (Fig. E2 & E15) This
peak is the ∆9-THCA peak which was originally added to the bacteria medium and when
compared to Figure 22, the elution time is at approximately the same time as the major
peak in Figure 22. As the incubation time progressed, this peak corresponding to ∆9THCA decreased in size and its elution time shifts to 14.5 minutes (aliquot for time =
3 hr) (Fig. E6).
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As the original large ∆9-THCA peak decreased in size, simultaneously a peak
with a shorter elution time increased in size. This peak is first visible in the time one-hour
aliquot at approximately 9.3 minutes. This peak increased from aliquot to aliquot until it
is clearly visible at 8.3 minutes in the six-hour aliquot (Fig. E13 & E14). The ∆9-THCA
peak decreasing in size and the ∆9-THC peak increasing in size would indicate that over
time in this setup, ∆9-THCA is being converted to ∆9-THC. However, this peak does not
elute at the time which the ∆9-THC does in the ∆9-THC standard (Fig. E1). Additionally,
this peak appears in the control assay in the time = 1 hr, time = 3 hr, time = 4 hr, and
time = 6 hr aliquots (Fig. E16, E18, E19, E20, E22, & E23). This indicates that this peak
could be a component of the cell media which is being extracted along with the
cannabinoids.
Several of these aliquots were analyzed via analytical HPLC multiple times due to
irregularities in the chromatograms. For example, the time = 2 hr aliquot was analyzed
twice (Fig. E4 & E5). On the second analysis (Fig. E5), from 11.5 minutes to 14.5
minutes several peaks eluted which did not appear in the first chromatogram (Fig. E4),
indicating that some component from previous injections may have been adhering to the
column and eluting in later sample runs. This phenomenon was seen again when
comparing the two analyses for the time = 3 hr aliquot (Fig. E6 & E7), the three analyses
for the time = 4 hr aliquot (Fig. E8 – E10), the two analyses for the time = 5 aliquot (Fig.
E11 & E12), and the two analyses for the time = 6 hr aliquot (Fig. E13 & E14). This
brings all of the peaks observed in this assay into question, since this allows for the
possibility of some component adhering to the column and eluting at any time during any
sample.
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After all the aliquots were analyzed via analytical HPLC, two cleaning methods
were developed for the analytical HPLC which were run in hopes of removing all the
compounds adhering to the column. The first cleaning method was five hours long; line
A was HPLC-grade acetonitrile and line B was HPLC-grade water. The run began with
60% A and increased to 95% A over 10 minutes. It was held at this concentration for 280
minutes, and in the last ten minutes decreased to 60% A. The second cleaning method
was five hours long; line A was HPLC-grade methanol and line B was HPLC-grade
water. The run began with 60% A and increased to 95% A over 10 minutes. It was held at
this concentration for 280 minutes, and in the last ten minutes decreased to 60% A.
Third P. putida Assay
All the chromatograms of aliquots taken in this assay are in Appendix F.
Immediately it was apparent that the flush methods developed to clean the column after
the previous assay were not effective. The ∆9-THC standard analysis showed the ∆9-THC
peak eluting at 10.8 minutes. There were several additional peaks eluting from 8 minutes
to 10.2 minutes and 11.2 minutes to 16.0 minutes (Fig. F1). These peaks were visible in
all the other aliquots analyzed for this assay (Fig. F2 – F15). The time = 0 hr aliquot and
the time = 0 hr control aliquot have a major peak which eluted at 11.0 minutes (Fig. F2 &
F9). This was the ∆9-THCA peak. This peak was visible in all other aliquots analyzed in
this assay. However, if there was any decarboxylation, the peak for the ∆9-THC produced
was buried in the multiple peaks resulting from cannabinoids adhering to the column.
This made the assay uninterpretable. The final analysis conducted for this assay was that
of a sample of absolute ethanol to show the peaks which were due to the accumulation of
compounds adhering to the column (Fig. F16).
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More intensive flush methods were developed for the analytical HPLC and were
run before the next assay to avoid a repetition of this problem. The first step of the flush
method was running an isocratic method of 95% HPLC-grade water, and 5% HPLCgrade acetonitrile at a flow rate of 1.0 mL/min for 35 minutes. This was followed by an
isocratic method of 95% HPLC-grade acetonitrile, and 5% isopropanol at a flow rate of
1.0 mL/min for 35 minutes. This was followed by an isocratic method of 95%
isopropanol, and 5% HPLC-grade hexane at a flow rate of 1.0 mL/min for 9 minutes.
This was followed by an isocratic method of 95% HPLC-grade hexane, and 5%
isopropanol at a flow rate of 1.0 mL/min for 35 minutes. This was followed by an
isocratic method of 95% isopropanol, and 5% HPLC-grade acetonitrile at a flow rate of
1.0 mL/min for 9 minutes. The method finishes with an isocratic method of 95% HPLCgrade acetonitrile, and 5% HPLC-grade water at a flow rate of 1.0 mL/min for 35
minutes. In between each of these isocratic methods a 5-minute-long gradient method
was run to slowly adjust the type of the solvent used for each isocratic run described.
Fourth P. putida Assay
All the chromatograms of aliquots taken in this assay are in Appendix G. There
was one major peak at approximately 10.5 minutes for both the time = 0 hr aliquot and
the time = 0 hr control aliquot (Fig. G2 & G9). This peak represents the ∆9-THCA added
at the start of the assay (Fig. G1). A peak eluted at approximately 7.8 minutes and
another at approximately 8.2 minutes in the time = 1 hr, time = 3 hr, time = 4 hr, and
time = 5 hr samples, as well as in the control time = 3 hr, and time = 5 hr samples. Since
these peaks appeared in both the control samples as well as the experimental samples,
they were most likely compounds extracted along with the cannabinoids originally in the
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cell media. If there was any decarboxylation activity of ∆9-THCA by the cell line, a peak
for ∆9-THC would elute at an earlier time than the observed ∆9-THCA peak, which eluted
at 10.7 minutes (Fig. G1). This ∆9-THC peak would appear in aliquots collected towards
the end of the assay. There were no peaks with a retention time of ∆9-THC which eluted
in any of the aliquots collected in this assay (Fig. G2 – G15) indicating that there was no
decarboxylation activity.
Fifth P. putida Assay
All the chromatograms of aliquots taken in this assay are in Appendix H. There
was one major peak at approximately 10.5 minutes for both the time = 0 hr aliquot and
the time = 0 hr control aliquot (Fig. H4 & H11). This peak represents the ∆9-THCA
added at the start of the assay (Fig. H3). The ∆9-THC standard was analyzed via
analytical HPLC before the aliquot samples from the assay and the ∆9-THC had an
elution time of 9.8 minutes (Fig. H2). There were no peaks visible at the elution time for
∆9-THC in any of the samples analyzed during this assay (Fig. H4 – H17).
To ensure that the ∆9-THC and the ∆9-THCA peaks were not buried within each
other on the chromatogram, and additional 0.1 mg of ∆9-THCA was added to the sample
from time = 1 hr and to the sample from time = 3 hr and each were analyzed via
analytical HPLC again (Fig. H18 & H19). Additionally, 0.12 mg of ∆9-THC standard was
added to a 0.1 mL aliquot of the sample from time = 1 hr and analyzed via analytical
HPLC (Fig. H20). Both samples which had additional ∆9-THCA added to them had a
peak which eluted at approximately 10.2 minutes (Fig. H18 & H19). Compared to the
chromatograms of these samples before they had the added ∆9-THCA (Fig. H7 & H5,
respectively), all four samples had a major peak which eluted between 10.0 and 10.7
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minutes. The samples depicted in Figures H18 and H19 had larger peaks at this elution
time than the samples with similar peaks in Figures H7 and H5. The sample from time =
1 hr which had an added 0.12 mg of ∆9-THC standard had one peak which eluted at 9.8
minutes and a second which eluted at 10.2 minutes (Fig. H20). The peak which eluted at
9.8 minutes was the ∆9-THC standard, and the peak which eluted at 10.2 minutes was the
∆9-THCA added to the microbial solution at the start of the assay (Fig. H2, H3, & H20).
This demonstrated that if there was a decarboxylation of the ∆9-THCA during this assay,
the ∆9-THC produced would elute as a separate peak from the ∆9-THCA. Since there was
not a peak visible at the elution time of 9.8 minutes in any of the samples, and the
additional analyses of aliquots with added ∆9-THCA and ∆9-THC which show that they
would elute at different time, it was determined that there was no ∆9-THCA
decarboxylation activity in this assay (Fig. H4 – H20).
Analysis of Fifth P. putida Assay Using
the ∆9-Tetrahydrocannabinolic Acid
Calibration Curve
The fifth P. putida assay was conducted using 16.0 mL of a 68.7 mg/mL
microbial solution which was incubated with 0.1 mL of 4 mg/mL ∆9-THCA isolated
using the preparative HPLC method (Fig. 30). This was assessed alongside a control
autoclaved microbial cell assay which consisted of 16.0 mL of a 60.60 mg/mL microbial
solution which was also incubated with 0.1 mL of 4 mg/mL ∆9-THCA isolated using the
preparative HPLC method (Fig. 30). Each 2-mL aliquot therefore should contain
approximately 0.025 mg/mL of ∆9-THCA. The area under the curve of the ∆9-THCA
peak in each of the aliquots can be determined using the CLASS-VP 7.2.1 SP1 software
program, and then using the equation from Figure 32, y = 1E+07x + 6E+06, the
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concentration of ∆9-THCA in each sample can be determined. These data are displayed in
Table 6.
Table 6
Calculation of the Concentration of ∆9-THCA in Each of the Aliquots Collected During
the Fifth P. putida Assay Using the ∆9-THCA Calibration Curve.

Aliquot
Area under the curve (AU)
Time = 0 hr
175840
Time = 1 hr
329167
Time = 2 hr
443777
Time = 3 hr
706271
Time = 4 hr
343161
Time = 5 hr
263011
Time = 6 hr
592775
Time = 0 hr control
711068
Time = 1 hr control
712563
Time = 2 hr control
653856
Time = 3 hr control
641541
Time = 4 hr control
542118
Time = 5 hr control
769166
Time = 6 hr control
604389
* calculated using the equation from Figure 32

Concentration of ∆9-THCA
(mg/mL)*
-0.582416
-0.5670833
-0.5556223
-0.5293729
-0.5656839
-0.5736989
-0.5407225
-0.5288932
-0.5287437
-0.5346144
-0.5358459
-0.5457882
-0.5230834
-0.5395611

All the calculated values for the concentration of ∆9-THCA in the samples from
the fifth assay were negative. It was previously calculated that each 2-mL aliquot should
contain approximately 0.025 mg/mL of ∆9-THCA. This value is smaller than the smallest
concentration in the calibration curve, so it is expected that these calculations could not
be completely accurate. However, they do show that each aliquot contains approximately
the same amount of ∆9-THCA.

CHAPTER V
CONCLUSIONS AND FUTURE WORK
There were two purposes of this study. First, was to produce a method of isolating
∆9-THCA from marijuana plant material. The second was to attempt to determine a cell
line containing an enzyme capable of decarboxylating ∆9-THCA, converting it to ∆9THC. This has significance to a future chemotherapy drug delivery system using Cell-ina-Box® technology. Pseudomonas putida was assayed to determine if it had any
decarboxylation activity for the ∆9-THCA. The ∆9-THCA used to assay the cell lines was
isolated from marijuana plant material in-house. Two methods for producing a crude
extract of cannabinoids from the plant material were developed, as well as two methods
for isolating the ∆9-THCA from these crude extracts.
Isolation of ∆9-Tetrahydrocannabinolic Acid
The Soxhlet extraction method for producing crude cannabinoid extract required
much less physical work compared to the sonication extraction method. The crude
extracts were further purified via either preparative HPLC or Yamazen Smart Flash
chromatography. Both methods were effective for the purification of ∆9-THCA from the
crude extract but to different degrees of purity. The ∆9-THCA isolate obtained from both
the HPLC and the Yamazen methods were analyzed via proton NMR and analytical
HPLC to compare their relative purity. Comparing the analytical HPLC analysis of the
∆9-THCA isolates from both the preparative HPLC method (Fig.38) and the Yamazen
method (Fig.24), using the preparative HPLC method was able to isolate ∆9-THCA
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almost entirely, whereas the sample containing ∆9-THCA obtained using Yamazen Smart
Flash method contained a mixture of other compounds. Additionally, when assessing the
percent yield of ∆9-THCA from 13.5% ∆9-THCA marijuana using each of the isolation
methods, the preparative HPLC method has a much higher percent yield than the
Yamazen method (99.3% and 27.1%, respectively).
The method of isolating ∆9-THCA from a crude extract of cannabinoids using the
Yamazen Smart Flash could be improved through further experimentation with reverse
phase TLC plates. The Yamazen uses a TLC plate when making its solvent system, and
the better resolved the compound is on the TLC plate, the better it will be isolated when
employing the Yamazen. The TLC plate were developed in 80% acetonitrile, 10%
methanol, and 10% 20 mM ammonium formate, pH 3.20. This did result in the ∆9-THCA
having an Rf of approximately 0.2, but there was some streaking on the plate, meaning
the ∆9-THCA spot was not totally pure. Further tweaking of the solvent system could
result in a TLC plate with less streaking which would lead to better separation when
using the instrument.
Another option is reinjecting the ∆9-THCA isolate initially collected from the
Yamazen Smart Flash (fraction 4 from Fig. 20) into the Yamazen for a second time to
further isolate the ∆9-THCA. This could be done using the same solvent system and TLC
plate as the first injection. However, better separation could be possible if further TLC
experimentation was conducted with the initial ∆9-THCA isolate collected from the
Yamazen. This ∆9-THCA isolated could be spotted on a TLC plate along with the ∆9THCA isolate collected via preparative HPLC (fraction 26 from Fig. 26), the ∆9-THC
standard, and the mixture of cannabinoids obtained from Cayman Chemical Company.
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Then a variety of solvent systems could be tested to develop TLC plates with these spots
to determine a solvent system able to isolate the ∆9-THCA from the other compounds
collected in the initial Yamazen isolate. The ∆9-THCA isolate collected from the
preparative HPLC, the ∆9-THC standard, and the mixture of cannabinoids will allow for
identification of the spots in the ∆9-THCA isolate mixture obtained from the Yamazen.
Once a TLC solvent system which can separate the ∆9-THCA from the other compounds
in the Yamazen sample, it can be reinjected into the Yamazen Smart Flash using this
solvent system and TLC plate to develop the method.
Additionally, when comparing the preparative HPLC method and the Yamazen
Smart Flash method it can be noted that the preparative HPLC method uses 750 mL of
mobile phase, and the Yamazen method uses 800 mL of mobile phase, along with 80 mL
of HPLC-grade water (see Methods). This is not a significant difference in volume when
considering sustainability; however, there is a major sustainability difference between the
methods when taking the columns that each use into consideration. The preparative
HPLC column used in this study which was sold by Phenomenex with the intention that it
will be used many times. Both the Yamazen inject column, and the universal column
used in this study were single use columns. Comparing both these methods of the
isolation of ∆9-THCA in a long-term time frame, the fact that the Yamazen columns need
to be replaced more often, and that the method uses more solvent, the Yamazen method
would be more expensive than the preparative HPLC method, and less sustainable.
Assessment of ∆9-Tetrahydrocannabinolic Acid
Decarboxylation in Different Cell Lines
Since the multiple Pseudomonas putida assays indicated that this cell line most
likely does not have an enzyme which efficiently decarboxylates ∆9-THCA to ∆9-THC,
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more cell lines need to be assayed. Other options of bacteria or fungi cell lines are those
which were discussed in the literature review, including Aspergillus clavatus, Aspergillus
giganteus, Aspergillus longivesica, Byssochlamys nivea, Penicillium expansum,
Trichosporon moniliiforme, Aspergillus oryzae, Aspergillus niger, Acinetobacter
calcoaceticus, Alcaligenes eutrophus, and Pseudomonas cepacia. Once a cell line able to
convert ∆9-THCA to ∆9-THC is identified, the specific gene and enzyme responsible for
this conversion needs to be identified. Then, through genetic engineering, this gene can
be inserted into a human embryonic kidney cell. This embryonic kidney cell line is what
Austranova would encapsulate using their novel cellulose-based polymer (Cell-in-aBox®). Finally, these cells can be explored as a possible novel chemotherapy treatment,
using ∆9-THCA as a pro-drug which would be converted to ∆9-THC at the location of the
tumor where the encapsulated cells are injected into the patient.
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APPENDIX A
Phenomenex Mixture of Cannabinoids Chromatogram

77

Phenomenex’s chromatogram of a mixture of cannabinoids containing CBDV, CBD,
CBG, CBDA, CBGA, CBN, ∆9-THCA, ∆9-THC, ∆8-THC, and CBC, chromatographed
on a Luna Omega 1.6 μm polar C18 100Ǻ column with a fifteen-minute-long method.
Line A was 20 mM 3.20 pH ammonium formate, and line B was acetonitrile. The method
began at 60% B, which was raise to 95% B over 12 minutes, held at 95% B for one
minute, and then at 13.01 minutes reduced to 60% B and held there until the end of the
run.

Figure A1: Chromatograph of mixture of cannabinoids containing CBDV (1), CBD (2),
CBG (3), CBDA (4), CBGA (5), CBN (6), ∆9-THC (7), ∆8-THC (8), CBC (9), and
∆9-THCA (10) (from “Cannabinoids on Luna Omega Polar C18 100x2.1mm”, n.d.).
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APPENDIX B
Nuclear Magnetic Resonance Spectra of Peaks
Collected via Yamazen Chromatography

79

The following are the NMR spectra for the peaks collected via Yamazen chromatography
which did not appear to contain any ∆9-THCA.

Figure B1: Proton NMR chromatogram of fraction 1 (from Figure 20).
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Figure B2: Proton NMR chromatogram of fraction 2 (from Figure 20).
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APPENDIX C
Nuclear Magnetic Resonance Spectra of Peaks Collected
via Preparative High-Performance Liquid
Chromatography
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The following are the NMR spectra for the peaks collected via preparative HPLC which
did not appear to contain any ∆9-THCA.

Figure C1: Proton NMR spectra of fraction 14 (from Figure 26).

83

Figure C2: Proton NMR spectra of fraction 22 (from Figure 26).

Figure C3: Proton NMR spectra of fraction 23 (from Figure 26).
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Figure C4: Proton NMR spectra of fraction 24 (from Figure 26).

Figure C5: Proton NMR spectra of fraction 25 (from Figure 26).
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APPENDIX D
First P. putida Assay
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The first Pseudomonas putida assay was conducted using 16.0 mL of a 24.4 mg/mL
microbial solution. The microbial cells were incubated with 0.1 mL of approximately 85
mg/mL ∆9-THCA isolated using the Yamazen method (Fig. 22). This is the only assay
which was not run along side a control autoclaved microbial cell assay. The ∆9-THC
standard and the mix of cannabinoid standards were analyzed via analytical HPLC before
the aliquots for this assay to identify the peaks in the aliquot samples.

Figure D1: Analytical HPLC method chromatogram of cannabinoid mixture standard
containing CBDA, CBGA, CBG, CBD, THCV, CBN, ∆9-THCA, ∆9-THC, ∆8-THC, and
CBC (100 μg/mL each in acetonitrile).

Figure D2: Analytical HPLC method chromatogram of ∆9-THC standard (1.2 mg/mL in
ethanol).
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Figure D3: Chromatogram of time = 0 hr aliquot of incubation of ∆9-THCA with P.
putida.

Figure D4: Chromatogram of time = 1 hr aliquot of incubation of ∆9-THCA with P.
putida.

Figure D5: Repeat of chromatogram of time = 1 hr aliquot of incubation of ∆9-THCA
with P. putida.
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Figure D6: Second repeat of chromatogram of time = 1 hr aliquot of incubation of ∆9THCA with P. putida.

Figure D7: Third repeat of chromatogram of time = 1 hr aliquot of incubation of ∆9THCA with P. putida.

Figure D8: Chromatogram of time = 2 hr aliquot of incubation of ∆9-THCA with P.
putida.

89

Figure D9: Repeat of chromatogram of time = 2 hr aliquot of incubation of ∆9-THCA
with P. putida.

Figure D10: Chromatogram of time = 3 hr aliquot of incubation of ∆9-THCA with P.
putida.

Figure D11: Chromatogram of time = 4 hr aliquot of incubation of ∆9-THCA with P.
putida.
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Figure D12: Chromatogram of time = 5 hr aliquot of incubation of ∆9-THCA with P.
putida.

Figure D13: Chromatogram of time = 6 hr aliquot of incubation of ∆9-THCA with P.
putida.
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APPENDIX E
Second P. putida Assay
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The second Pseudomonas putida assay was conducted using 16.0 mL of a 22.3 mg/mL
microbial solution. The microbial cells were incubated with 0.1 mL of approximately 85
mg/mL ∆9-THCA isolated using the Yamazen method (Fig. 22). This was run alongside a
control autoclaved microbial cell assay which consisted of 16.0 mL of a 25.5 mg/mL
microbial solution which was incubated with 0.1 mL of approximately 85 mg/mL ∆9THCA isolated using the Yamazen method (Fig. 22). The ∆9-THC standard was analyzed
via analytical HPLC before the aliquots for this assay to identify the peaks in the aliquot
samples.

Figure E1: Analytical HPLC method chromatogram of ∆9-THC standard (1.2 mg/mL in
ethanol).

Figure E2: Chromatogram of time = 0 hr aliquot of incubation of ∆9-THCA with P.
putida.
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Figure E3: Chromatogram of time = 1 hr aliquot of incubation of ∆9-THCA with P.
putida.

Figure E4: Chromatogram of time = 2 hr aliquot of incubation of ∆9-THCA with P.
putida.

Figure E5: Repeat of chromatogram of time = 2 hr aliquot of incubation of ∆9-THCA
with P. putida.
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Figure E6: Chromatogram of time = 3 hr aliquot of incubation of ∆9-THCA with P.
putida.

Figure E7: Repeat of chromatogram of time = 3 hr aliquot of incubation of ∆9-THCA
with P. putida.

Figure E8: Chromatogram of time = 4 hr aliquot of incubation of ∆9-THCA with P.
putida.
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Figure E9: Repeat of chromatogram of time = 4 hr aliquot of incubation of ∆9-THCA
with P. putida.

Figure E10: Second repeat of chromatogram of time = 4 hr aliquot of incubation of ∆9THCA with P. putida.

Figure E11: Chromatogram of time = 5 hr aliquot of incubation of ∆9-THCA with P.
putida.
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Figure E12: Repeat of chromatogram of time = 5 hr aliquot of incubation of ∆9-THCA
with P. putida.

Figure E13: Chromatogram of time = 6 hr aliquot of incubation of ∆9-THCA with P.
putida.

Figure E14: Repeat of chromatogram of time = 6 hr aliquot of incubation of ∆9-THCA
with P. putida.
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Figure E15: Chromatogram of time = 0 hr control aliquot of incubation of ∆9-THCA with
P. putida.

Figure E16: Chromatogram of time = 1 hr control aliquot of incubation of ∆9-THCA with
P. putida.

Figure E17: Chromatogram of time = 2 hr control aliquot of incubation of ∆9-THCA with
P. putida.
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Figure E18: Chromatogram of time = 3 hr control aliquot of incubation of ∆9-THCA with
P. putida.

Figure E19: Chromatogram of time = 4 hr control aliquot of incubation of ∆9-THCA with
P. putida.

Figure E20: Repeat of chromatogram of time = 4 hr control aliquot of incubation of ∆9THCA with P. putida.
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Figure E21: Chromatogram of time = 5 hr control aliquot of incubation of ∆9-THCA with
P. putida.

Figure E22: Chromatogram of time = 6 hr control aliquot of incubation of ∆9-THCA with
P. putida.

Figure E23: Repeat of chromatogram of time = 6 hr control aliquot of incubation of ∆9THCA with P. putida.
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APPENDIX F
Third P. putida Assay
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The third Pseudomonas putida assay was conducted using 16.0 mL of a 55.5 mg/mL
microbial solution. The microbial cells were incubated with 0.1 mL of approximately 85
mg/mL ∆9-THCA isolated using the Yamazen method (Fig. 22). This was run alongside a
control autoclaved microbial cell assay which consisted of 16.0 mL of a 20.0 mg/mL
microbial solution which was incubated with 0.1 mL of approximately 85 mg/mL ∆9THCA isolated using the Yamazen method (Fig. 22). The ∆9-THC standard was analyzed
via analytical HPLC before the aliquots for this assay to identify the peaks in the aliquot
samples. After the aliquot samples were analyzed a sample of absolute ethanol was
analyzed to see the amount of contamination stuck to the column.

Figure F1: Analytical HPLC method chromatogram of ∆9-THC standard (1.2 mg/mL in
ethanol).

Figure F2: Chromatogram of time = 0 hr aliquot of incubation of ∆9-THCA with P.
putida.
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Figure F3: Chromatogram of time = 1 hr aliquot of incubation of ∆9-THCA with P.
putida.

Figure F4: Chromatogram of time = 2 hr aliquot of incubation of ∆9-THCA with P.
putida.

Figure F5: Chromatogram of time = 3 hr aliquot of incubation of ∆9-THCA with P.
putida.
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Figure F6: Chromatogram of time = 4 hr aliquot of incubation of ∆9-THCA with P.
putida.

Figure F7: Chromatogram of time = 5 hr aliquot of incubation of ∆9-THCA with P.
putida.

Figure F8: Chromatogram of time = 6 hr aliquot of incubation of ∆9-THCA with P.
putida.
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Figure F9: Chromatogram of time = 0 hr control aliquot of incubation of ∆9-THCA with
P. putida.

Figure F10: Chromatogram of time = 1 hr control aliquot of incubation of ∆9-THCA with
P. putida.

Figure F11: Chromatogram of time = 2 hr control aliquot of incubation of ∆9-THCA with
P. putida.
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Figure F12: Chromatogram of time = 3 hr control aliquot of incubation of ∆9-THCA with
P. putida.

Figure F13: Chromatogram of time = 4 hr control aliquot of incubation of ∆9-THCA with
P. putida.

Figure F14: Chromatogram of time = 5 hr control aliquot of incubation of ∆9-THCA with
P. putida.
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Figure F15: Chromatogram of time = 6 hr control aliquot of incubation of ∆9-THCA with
P. putida.

Figure F16: Chromatogram of absolute ethanol.

107

APPENDIX G
Fourth P. putida Assay
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The fourth Pseudomonas putida assay was conducted using 16.0 mL of a 65.5 mg/mL
microbial solution. The microbial cells were incubated with 0.1 mL of 2 mg/mL ∆9THCA isolated using the preparative HPLC method (Fig. 30). This was run alongside a
control autoclaved microbial cell assay which consisted of 16.0 mL of a 37.5 mg/mL
microbial solution which was incubated with 0.1 mL of 2 mg/mL ∆9-THCA isolated
using the preparative HPLC method (Fig. 30). The ∆9-THCA isolated via preparative
HPLC and the ∆9-THC standard were analyzed via analytical HPLC before the aliquots
for this assay to identify the peaks in the aliquot samples (Fig. G1 & G2).

Figure G1: Analytical HPLC method chromatogram of ∆9-THCA isolated via preparative
HPLC (2 mg/mL in ethanol).

Figure G2: Analytical HPLC method chromatogram of ∆9-THC standard (1.2 mg/mL in
ethanol).
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Figure G3: Chromatogram of time = 0 hr aliquot of incubation of ∆9-THCA with P.
putida.

Figure G4: Chromatogram of time = 1 hr aliquot of incubation of ∆9-THCA with P.
putida.

Figure G5: Chromatogram of time = 2 hr aliquot of incubation of ∆9-THCA with P.
putida.
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Figure G6: Chromatogram of time = 3 hr aliquot of incubation of ∆9-THCA with P.
putida.

Figure G7: Chromatogram of time = 4 hr aliquot of incubation of ∆9-THCA with P.
putida.

Figure G8: Chromatogram of time = 5 hr aliquot of incubation of ∆9-THCA with P.
putida.
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Figure G9: Chromatogram of time = 6 hr aliquot of incubation of ∆9-THCA with P.
putida.

Figure G10: Chromatogram of time = 0 hr control aliquot of incubation of ∆9-THCA
with P. putida.

Figure G11: Chromatogram of time = 1 hr control aliquot of incubation of ∆9-THCA
with P. putida.
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Figure G12: Chromatogram of time = 2 hr control aliquot of incubation of ∆9-THCA
with P. putida.

Figure G13: Chromatogram of time = 3 hr control aliquot of incubation of ∆9-THCA
with P. putida.

Figure G14: Chromatogram of time = 4 hr control aliquot of incubation of ∆9-THCA
with P. putida.
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Figure G15: Chromatogram of time = 5 hr control aliquot of incubation of ∆9-THCA
with P. putida.

Figure G16: Chromatogram of time = 6 hr control aliquot of incubation of ∆9-THCA
with P. putida.
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APPENDIX H
Fifth P. putida Assay
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The fifth Pseudomonas putida assay was conducted using 16.0 mL of a 68.7 mg/mL
microbial solution. The microbial cells were incubated with 0.1 mL of 4 mg/mL ∆9THCA isolated using the preparative HPLC method (Fig. 30). This was run alongside a
control autoclaved microbial cell assay which consisted of 16.0 mL of a 60.60 mg/mL
microbial solution which was incubated with 0.1 mL of 4 mg/mL ∆9-THCA isolated
using the preparative HPLC method (Fig. 30). The ∆9-THCA isolated via preparative
HPLC was analyzed via analytical HPLC, along with the ∆9-THC standard, and the
mixture of cannabinoids which contained CBDA, CBGA, CBG, CBD, THCV, CBN, ∆9THCA, ∆9-THC, ∆8-THC, and CBC (Fig. H1 – H3). This was done to identify the peaks
in the aliquot samples. After all the aliquot samples from this assay were analyzed, 0.1
mg of ∆9-THCA isolated via preparative HPLC was added to a 0.1 mL aliquot of the
sample from time = 1 hr and analyzed via analytical HPLC again (Fig. H18). This was
also repeated for the sample from time = 3 hr (Fig. H19). Additionally, 0.12 mg of ∆9THC standard was added to a 0.1 mL aliquot of the sample from time = 1 hr and analyzed
via analytical HPLC (Fig. H20).

Figure H1: Analytical HPLC method chromatogram of cannabinoid mixture standard
containing CBDA, CBGA, CBG, CBD, THCV, CBN, ∆9-THCA, ∆9-THC, ∆8-THC, and
CBC (100 μg/mL each in acetonitrile).
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Figure H2: Analytical HPLC method chromatogram of ∆9-THC standard (1.2 mg/mL in
ethanol).

Figure H3: Analytical HPLC method chromatogram of ∆9-THCA isolated via preparative
HPLC (4 mg/mL in ethanol).

Figure H4: Chromatogram of time = 0 hr aliquot of incubation of ∆9-THCA with P.
putida.
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Figure H5: Chromatogram of time = 1 hr aliquot of incubation of ∆9-THCA with P.
putida.

Figure H6: Chromatogram of time = 2 hr aliquot of incubation of ∆9-THCA with P.
putida.

Figure H7: Chromatogram of time = 3 hr aliquot of incubation of ∆9-THCA with P.
putida.

118

Figure H8: Chromatogram of time = 4 hr aliquot of incubation of ∆9-THCA with P.
putida.

Figure H9: Chromatogram of time = 5 hr aliquot of incubation of ∆9-THCA with P.
putida.

Figure H10: Chromatogram of time = 6 hr aliquot of incubation of ∆9-THCA with P.
putida.
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Figure H11: Chromatogram of time = 0 hr control aliquot of incubation of ∆9-THCA
with P. putida.

Figure H12: Chromatogram of time = 1 hr control aliquot of incubation of ∆9-THCA
with P. putida.

Figure H13: Chromatogram of time = 2 hr control aliquot of incubation of ∆9-THCA
with P. putida.
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Figure H14: Chromatogram of time = 3 hr control aliquot of incubation of ∆9-THCA
with P. putida.

Figure H15: Chromatogram of time = 4 hr control aliquot of incubation of ∆9-THCA
with P. putida.

Figure H16: Chromatogram of time = 5 hr control aliquot of incubation of ∆9-THCA
with P. putida.
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Figure H17: Chromatogram of time = 6 hr control aliquot of incubation of ∆9-THCA
with P. putida.

Figure H18: Chromatogram of time = 3 hr control aliquot of incubation of ∆9-THCA
with P. putida with 0.1 mg of added ∆9-THCA.

Figure H19: Chromatogram of time = 1 hr control aliquot of incubation of ∆9-THCA
with P. putida with 0.1 mg of added ∆9-THCA.
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Figure H20: Chromatogram of time = 1 hr control aliquot of incubation of ∆9-THCA
with P. putida with 0.12 mg of added ∆9-THC.

